CV for USYD October 2021 - api.profiles.sydney.edu.au

Georgina V. Long Curriculum Vitae September 2021

1

Georgina V. Long AO Melanoma Institute Australia and The University of Sydney

40 Rocklands Road, North Sydney NSW 2060 +61 2 9911 7336 | [email protected]

PROFILE

Professor Georgina Long AO, BSc PhD MBBS FRACP FAHMS, is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance. In recognition of her ground-breaking research and work, Professor Long was appointed as an Officer of the Order of Australia (2020) and has received several awards, including the Research Australia, GSK Research Excellence Award (2018) and prestigious Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016). She has a number of CINSW Premiers Awards, including; the Outstanding Cancer Researcher (2018), the Excellence in Translational Cancer Research Award (2017), the Wildfire Award for the most highly-cited, original, peer-reviewed article published (2011, 2014, 2016 & 2017), and in 2013 she was named the Outstanding Cancer Research Fellow. She is also Clarivate highly-cited Researcher for 2017-2020. Her H index is 107 and in August 2021 she was ranked the world’s 2nd, and Australia’s 1st melanoma expert in all fields and discipline (http://expertscape.com/ex/melanoma)

Professor Long is the author of over 340 peer-reviewed publications in clinical and translational research in melanoma, including the New England Journal of Medicine, Lancet, Lancet Oncology, Science, Nature, Lancet Oncology, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 200 occasions. She is Past President for the prestigious international Society for Melanoma Research (2018-2020), is a member and Chair of the ASCO (2015-2017) and ESMO (2017-2020) Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.

AWARDS AND DISTINCTIONS

Clarivate Analytics 2020 – Highly Cited Researcher – Clinical Medicine 2020

Order of Australia 2020

Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2017 2020 Hayward NK, Wilmott JW (Awardee J Wilmott – snr author) et al, Nature 2017, 545(7653):175-180

The Australian Newspaper – 2019 Research Magazine Named as Field Leader (Oncology) 2019

Clarivate Analytics 2019 Highly Cited Researcher – Clinical Medicine 2019

Australian Financial Review – 100 Women of Influence Award Finalist 2019


GSK Award for Research Excellence, Research Australia Health & Medical Research Awards 2018


2

Co-awardee Professor Richard Scolyer

Cancer Institute NSW Premiers Awards: Outstanding Cancer Researcher of the Year 2018


Cancer Institute NSW Premiers Awards: Wildfire Award, most cited article published in 2014 2017

Rizos H, Long GV (Awardee H Rizos – senior author) et al, Clinical Cancer Res 2014, 20(7):1965–1977

Cancer Institute NSW Premiers Awards: Excellence in Translational Cancer Research Award 2017

Co-awardees Professor Richard Scolyer and the Melanoma Institute Australia Translational Team

Fellowship of the Australian Academy of Health and Medical Sciences 2017


Long GV, Wilmott JS (Awardee JSW - shared 1st authorship) et al, Am J Surg Pathol 2013, 37:61.

Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research 2016

For extensive contributions to the field of melanoma research and clinical services

Society for Melanoma Research, Young Investigator Award 2016

Society for Melanoma Research 2015 International Congress, 18-21 November,

San Francisco, USA

Amgen Australia, Award for the Best Consultant Poster, Medical Oncology Group of 2015

Australia’s Annual Scientific Meeting in Hobart

Thomson Reuters Citation and Innovation Award for Outstanding Research 2015

For research in BRAF-mutated melanoma. Co-awardees Professor Richard Scolyer,

Professor Richard Kefford, Professor Grant McArthur

INSTYLE award for Women in Science and Technology 2015

Finalist, Pride of Australia Award for contribution to the community (Telegraph Newspaper) 2015


Long GV et al J Clin Oncol 2011, 29:1239-46

Top 5 most highly cited article 2012 for Clinical Cancer Research (IF 7.837) 2014

Long GV, Wilmott J (shared first authorship) Clin Can Res, 2012, 18:1386-94

Top 50 most highly cited article 2011 for Journal Clinical Oncology (IF18.97) 2013

Long GV et al J Clin Oncol 2011, 29:1239-46

Cancer Institute NSW Premiers award for Outstanding Cancer Research Fellow 2013

Nominated for Australian of the Year 2013 2013

Sir Roy McCaughey Fellowship, RACP 2013

Melanoma Research Alliance Young Investigator 2013-2016

Marjorie Hooper Scholarship, RACP 2012

Best published manuscript, Westmead Millennium Institute 2011

Development Fellowship, Cancer Institute NSW 2011

Career Development Grant, Cancer Institute NSW 2011

Australia Post Melanoma Fellowship, Cancer Institute NSW 2010

Cancer Institute NSW, Conference Grant 2010


3

ANZATAX, Advanced Trainee Travel Grant 2007

Amgen Australia, Advanced Trainee Grant, for best oral presentation MOGA 2006

DK Baird Bicentennial Travelling Fellowship, Royal Prince Alfred Hospital 2006

Esma May Harris Scholarship, Sydney University 1998, 1999

J B Watt Travelling Scholarship, Sydney University 1996, 1997

C G and R J W Le Fevre Postgraduate Student Lecture, Sydney University 1995

George Harris Postgraduate Prize, Sydney University 1995

James Kentley Memorial Scholarship, Sydney University 1994

G H S and I R Lightoller Scholarship, Sydney University 1994

R J W Le Fevre Travelling Scholarship, Sydney University 1994

Henry Bertie Florence Mable Gritton Postgraduate Scholarship 1993-1996

Australian Post Graduate Research Award, Sydney University 1993

University Medal for Organic Chemistry, Sydney University 1992

Janet Elspeth Crawford Prize, Chemistry, Sydney University 1992

Inglis Hudson Scholarship (major), Chemistry, Sydney University 1991

Vacation Scholarship, Research School of Chemistry, ANU, 1991-1992

Prof. D Evans – Molecular Dynamics

PUBLICATIONS (Key Cont r ibu t ions to Fie ld Bolded)

1. Dearden, H., Au, L. Wang, D. Y., Zimmer, L., Eroglu, Z., Smith, J. L., Cuvietto, M., Khoo, C., Atkinson, V., Lo, S., Long, G. V., Sandhu, S., Ascierto, P. A., Carlino, M. S., Johnson, D. B., Larkin, J., Menzies, A. M., Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy, Eur J Cancer, 2021 Aug;15 3:168-178. doi: 10.1016/j.ejca.2021.04.045. Epub 2021 Jun 25. PMID 34182268

2. Schadendorf, D., Robert, C., Dummer, R., Flaherty, K. T., Tawbi, H. A., Menzies, A. M., Banerjee, H., Lau, M., Long, G. V., Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers, Eur J Cancer. 2021 Jul 2; 153:234-241. doi: 10.1016/j.ejca.2021.05.005. Online ahead of print. PMID 34225229

3. Long, G. V., Robert, C., Butler, M. O., Couture, F., Carlino, M. S., O'Day, S., Atkinson, V., Cebon, J. S., Brown, M. P., Dalle, S.,Hill, A. G., Gibney, G. T., McCune, S., Menzies, A. M., Niu, C., Ibrahim, N., Homet Moreno, B., Diab, A., Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules, Clin Cancer Res. 2021 Jul 1; clincanres.0793.2021. doi: 10.1158/1078-0432.CCR-21-0793. Online ahead of print. PMID 34210681

4. Hepner, A., Atkinson, V. G., Larkin, J., Burrell, R. A., Carlino, M. S., Johnson, D. B., Zimmer, L., Tsai, K. K., Klein, O., Lo, S. N., Haydon, A., Bhave, P., ,Lyle, M., Pallan, L., Pires da Silva, I., Gerard, C., Michielin, O., Long, G. V., Menzies, A. M., Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy, Eur J Cancer, 2021 Jun 28; 153:213-222. doi: 10.1016/j.ejca.2021.04.021. Online ahead of print., PMID 34214936

5. Pires da Silva, I., Ahmed, T., Reijers, I. L. M., Weppler, A. M., Betof Warner, A., Patrinely, J. R., Serra-Bellver, P., Allayous, C., Mangana, J., Nguyen, K., Zimmer, L., Trojaniello, C., Stout, D., Lyle, M., Klein, O., Gerard, C. L., Michielin, O., Haydon, A., Ascierto, P. A., Carlino, M. S., Lebbe, C. Lorigan, P., Johnson, D. B., Sandhu, S., Lo, S. N. ,Blank, C. U., Menzies, A. M., Long, G. V., Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study, Lancet Oncol. 2021 Jun;22 (6):836-847. doi: 10.1016/S1470-2045(21)00097-8. Epub 2021 May 11. PMID: 33989557


4

6. Li, A. T., Maw, A. M., Hsiao, E., Ch'ng, S., Long, G. V., Shannon, K. F., Morrison, E. J., Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma, ANZ J Surg. 2021 Jun 14. doi: 10.1111/ans.16992. Online ahead of print. PMID 34124833

7. Ch'ng, S., Uyulmaz, S., Carlino, M. S., Pennington, T. E., Shannon, K. F., Rtshiladze, M., Stretch, J. R., Nieweg, O. E., Varey, A. H. R., Hsiao, E., Kapoor, R., Pires da Silva, I., Lo, S. N., Spillane, A. J., Scolyer, R. A., Long, G. V., Hong, A. M., Saw, R. P. M., Thompson, J. F., Menzies, A. M, Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies, Eur J Cancer. 2021 Jun 11; 153:8-15. doi: 10.1016/j.ejca.2021.04.037. Online ahead of print. PMID 34126335

8. Parakh, S., Musafer, A., Paessler, S., Witkowski, T., Suen, Csnlw, Tutuka, C. S. A., Carlino, M. S., Menzies, A. M., Scolyer, R. A., Cebon, J., Dobrovic, A., Long, G. V., Klein, O., Behren, A., PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma, Front Immunol,. 2021 Jun 9; 12:672521. doi: 10.3389/fimmu.2021.672521. eCollection 2021, PMID 34177913

9. Brase, J. C., Walter, R. F. H., Savchenko, A., Gusenleitner, D., Garrett, J., Schimming, T. T., Varaljai, R., Castelletti, D., Kim, J. Y., Dakappagari, N. K., Schultz, K., Robert, C., Long, G. V., Nathan, P. D., Ribas, A., Flaherty, K. T., Karaszewska, B., Schachter, J., Sucker, A., Schmid, K. W., Zimmer, L., Livingstone, E., Gasal, E., Schadendorf, D., Roesch, A., Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib, Clin Cancer Res. 2021 Jun 9 ;clincanres.3586.2020. doi: 10.1158/1078-0432.CCR-20-3586. Online ahead of print., PMID 34108180

10. Menzies, A. M., Scolyer, R. A., Long, G. V., Neoadjuvant immunotherapy in melanoma - the new frontier, Clin Cancer Res. 2021 Jun 3; clincanres.1236.2021. doi: 10.1158/1078-0432.CCR-21-1236. Online ahead of print., PMID 34083235

11. Rawson, R. V., Adhikari, C., Bierman, C., Lo, S. N., Shklovskaya, E., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Shannon, K. F., Gonzalez, M., Guminski, A. D., Tetzlaff, M. T., Stretch, J. R., Eriksson, H., van Thienen, J. V., Wouters, M. W., Haanen, Jbag, Klop, W. M. C., Zuur, C. L., van Houdt, W. J., Nieweg, O. E., Ch'ng, S., Rizos, H., Saw, R. P. M., Spillane, A. J., Wilmott, J. S., Blank, C. U., Long, G. V., van de Wiel, B. A., Scolyer, R. A., Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma, Ann Oncol. 2021 Jun;3 2(6):766-777. doi: 10.1016/j.annonc.2021.03.006. Epub 2021 Mar 17, PMID: 33744385

12. Knispel, S., Gassenmaier, M., Menzies, A. M., Loquai, C., Johnson, D. B., Franklin, C., Gutzmer, R., Hassel, J. C., Weishaupt, C., Eigentler, T., Schilling, B., Schummer, P., Sirokay, J., Kiecker, F., Owen, C. N., Fleischer, M. I., Cann, C., Kahler, K. C., Mohr, P., Bluhm, L., Niebel, D., Thoms, K. M., Goldinger, S. M., Reinhardt, L., Meier, F., Berking, C., Reinhard, R., Susok, L., Ascierto, P. A., Drexler, K., Pfohler, C., Tietze, J., Heinzerling, L., Livingstone, E., Ugurel, S., Long, G. V., Stang, A., Schadendorf, D., Zimmer, L., Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition, Eur J Cancer. 2021 May;14 8:61-75. doi: 10.1016/j.ejca.2021.01.034. Epub 2021 Mar 15, PMID 33735811

13. Wu, S. Z., Roden, D. L.,Al-Eryani, G., Bartonicek, N., Harvey, K., Cazet, A. S., Chan, C. L., Junankar, S., Hui, M. N., Millar, E. A., Beretov, J., Horvath, L., Joshua, A. M., Stricker, P., Wilmott, J. S., Quek, C., Long, G. V., Scolyer, R. A., Yeung, B. Z., Segara, D., Mak, C., Warrier, S., Powell, J. E., O'Toole, S., Lim, E., Swarbrick, A., Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis, Genome Med. 2021 May 10;13(1):81. doi: 10.1186/s13073-021-00885-z, PMID 33971952

14. Brown, L. J., Weppler, A., Bhave, P., Allayous, C., Patrinely, J. R., Jr., Ott, P., Sandhu, S., Haydon, A., Lebbe, C., Johnson, D. B., Long, G. V., Menzies, A. A., Carlino, M. S., Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders, J Immunother Cancer. 2021 May;9 (5):e002121. doi: 10.1136/jitc-2020-002121, PMID 33963010

15. Versluis, J. M., Hendriks, A. M., Weppler, A. M., Brown, L. J., de Joode, K., Suijkerbuijk, K. P. M., Zimmer, L., Kapiteijn, E. W., Allayous, C., Johnson, D. B., Hepner, A., Mangana, J., Bhave, P., Jansen, Y. J. L., Trojaniello, C., Atkinson, V., Storey, L., Lorigan, P, Ascierto, P. A. Neyns, B., Haydon, A., Menzies, A. M., Long, G. V., Lebbe, C., van der Veldt, A. A. M., Carlino, M. S., Sandhu, S., van Tinteren, H., de Vries, E. G. E., Blank, C. U., Jalving, M., The Role of Local Therapy in the Treatment


5

of Solitary Melanoma Progression upon Immune Checkpoint Inhibition: A Multicenter Retrospective Analysis; Eur J Cancer. 2021 May 7;151:72-83. doi: 10.1016/j.ejca.2021.04.003. Online ahead of print.. PMID 33971447

16. Park, J. J., Diefenbach, R. J., Byrne, N., Long, G. V., Scolyer, R. A., Gray, E. S., Carlino, M. S., Rizos, H., Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition, Cancers (Basel). 2021 Apr 6; 13(7):1740. doi: 10.3390/cancers13071740, PMID 33917514

17. Owen, C. N., Bai, X., Quah, T., Lo, S. N., Allayous, C., Callaghan, S., Martinez-Vila, C., Wallace, R., Bhave, P., Reijers, I. L. M., Thompson, N., Vanella, V., Gerard, C. L., Aspeslagh, S., Labianca, A., Khattak, A., Mandala, M., Xu, W., Neyns, B., Michielin, O., Blank, C. U., Welsh, S. J., Haydon, A., Sandhu, S., Mangana, J., McQuade, J. L., Ascierto, P. A., Zimmer, L., Johnson, D. B., Arance, A., Lorigan, P., Lebbe, C., Carlino, M. S., Sullivan, R. J., Long, G. V., Menzies, A. M., Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma, Ann Oncol. 2021 Mar 30; S0923-7534(21)01101-7. doi: 10.1016/j.annonc.2021.03.204. Online ahead of print, PMID 33798657

18. Patrinely, J. R., Jr., Johnson, R., Lawless, A. R., Bhave, P., Sawyers, A., Dimitrova, M., Yeoh, H. L., Palmeri, M., Ye, F., Fan, R., Davis, E. J., Rapisuwon, S., Long, G. V., Haydon, A., Osman, I., Mehnert, J. M., Carlino, M. S., Sullivan, R. J., Menzies, A. M., Johnson, D. B., Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma, JAMA Oncol. 2021 Mar 25. doi: 10.1001/jamaoncol.2021.0051. Online ahead of print. PMID: 33764387

19. F. Dimitriou, G.V. Long, A.M. Menzies, Novel adjuvant options for cutaneous melanoma, Ann Oncol. 2021 Mar 24; S0923-7534(21)01077-2. doi: 10.1016/j.annonc.2021.03.198. Online ahead of print, PMID: 33771664

20. Lee, H., Da Silva, I. P., Palendira, U., Scolyer, R. A., Long, G. V., Wilmott, J. S., Targeting NK Cells to Enhance Melanoma Response to Immunotherapies, Cancers (Basel). 2021 Mar 17; 13(6):1363. doi: 10.3390/cancers13061363., PMID 33802954

21. Versluis, J. M., Reijers, I. L. M., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Wouters, M. W., Ch'ng, S., Saw, R. P. M., Scolyer, R. A., van de Wiel, B. A., Schilling, B., Long, G. V., Blank, C. U., Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma, Eur J Cancer. 2021 Mar 15;148:51-57. doi: 10.1016/j.ejca.2021.02.012. Online ahead of print, PMID: 33735809

22. Kramer, R., Zaremba, A., Moreira, A., Ugurel, S., Johnson, D. B., Hassel, J. C., Salzmann, M., Gesierich, A., Weppler, A., Spain, L., Loquai, C., Dudda, M., Pfohler, C., Hepner, A., Long, G. V., Menzies, A. M., Carlino, M. S., Sachse, M. M., Lebbe, C., Baroudjian, B., Enokida, T., Tahara, M., Schlaak, M., Hayani, K., Brockelmann, P. J., Meier, F., Reinhardt, L., Friedlander, P., Eigentler, T., Kahler, K. C., Berking, C., Zimmer, L., Heinzerling, L., Hematological immune related adverse events after treatment with immune checkpoint inhibitors, Eur J Cancer. 2021 Mar 8;147:170-181. doi: 10.1016/j.ejca.2021.01.013. Online ahead of print. PMID: 33706206

23. Menzies, A. M., Amaria, R. N., Rozeman, E. A., Huang, A. C., Tetzlaff, M. T., van de Wiel, B. A., Lo, S., Tarhini, A. A., Burton, E. M., Pennington, T. E., Saw, R. P. M., Xu, X., Karakousis, G. C., Ascierto, P. A., Spillane, A. J., van Akkooi, A. C. J., Davies, M. A., Mitchell, T. C., Tawbi, H. A., Scolyer, R. A., Wargo, J. A., Blank, C. U., Long, G. V., Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) Nat Med . 2021 Feb;27(2):301-309. doi: 10.1038/s41591-020-01188-3. Epub 2021 Feb 8. PMID 33558722

24. Garg, M., Couturier, D. L., Nsengimana, J., Fonseca, N. A., Wongchenko, M., Yan, Y., Lauss, M., Jonsson, G. B., Newton-Bishop, J., Parkinson, C., Middleton, M. R., Bishop, D. T., McDonald, S., Stefanos, N., Tadross, J., Vergara, I. A., Lo, S., Newell, F., Wilmott, J. S., Thompson, J. F., Long, G. V., Scolyer, R. A., Corrie, P., Adams, D. J., Brazma, A., Rabbie, R, Tumour gene expression signature in primary melanoma predicts long-term outcomes, Nat Commun. 2021 Feb 18;12(1):1137. doi: 10.1038/s41467-021-21207-2., PMID 33602918

25. Olofsson Bagge, R., Ny, L, Ascierto, P. A, Hodi, F. S, Larkin, J, Robert, C, Schachter, J, Weber, J. S, Long, G. V, van Akkooi, A. C. J, The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials, Melanoma Res. 2021 Feb 18. doi: 10.1097/CMR.0000000000000719. Online ahead of print, PMID: 33625104

26. Kelly, G. M.,Al-Ejeh, F., McCuaig, R., Casciello, F., Ahmad Kamal, N., Ferguson, B., Pritchard, A. L., Ali, S., Silva, I. P, Wilmott, J. S., Long, G. V., Scolyer, R. A., Rao, S., Hayward, N. K., Gannon, F., Lee,


6

J. S., G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma, Clin Cancer Res. 2021 Feb 15. doi: 10.1158/1078-0432.CCR-20-3463. Online ahead of print. PMID: 33589432

27. Syeda, M. M., Wiggins, J. M., Corless, B. C., Long, G. V., Flaherty, K. T., Schadendorf, D., Nathan, P. D., Robert, C., Ribas, A., Davies, M. A., Grob, J. J., Gasal, E., Squires, M., Marker, M., Garrett, J., Brase, J. C., & Polsky, D. (2021). Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study, Lancet Oncol. 2021 Feb 12;S1470-2045(20)30726-9. doi: 10.1016/S1470-2045(20)30726-9. Online ahead of print, PMID: 33587894

28. Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L. G., Shannon, K., Haanen, J., Stretch, J., Ch'ng, S., Nieweg, O. E., Mallo, H. A., Adriaansz, S., Kerkhoven, R. M., Cornelissen, S., Broeks, A., Klop, W. M. C., Zuur, C. L., van Houdt, W. J., Peeper, D. S., Spillane, A. J., van Akkooi, A. C. J., Scolyer, R. A., Schumacher, T. N. M., Menzies, A. M., Long, G. V., & Blank, C. U. (2021). Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma, Nat Med. 2021 Feb 8. doi: 10.1038/s41591-020-01211-7. Online ahead of print. PMID 33558721

29. Patrinely, J. R., Jr., McGuigan, B., Chandra, S., Fenton, S. E., Chowdhary, A., Kennedy, L. B., Mooradian, M. J., Palmeri, M., Portal, D., Horst, S. N., Scoville, E. A., Long, G. V., Shi, C., Mehnert, J. M., Sullivan, R. J., Salama, A. K., Sosman, J. A., Menzies, A. M., Johnson, D. B., A multicenter characterization of hepatitis associated with immune checkpoint inhibitors, Oncoimmunology, . 2021 Feb 8;10(1):1875639. doi: 10.1080/2162402X.2021.1875639. PMID 33628621

30. Simpson, R. C., Shanahan, E., Scolyer, R. A., & Long, G. V. Targeting the Microbiome to Overcome Resistance, Cancer Cell. 2021 Feb 8;39(2):151-153. doi: 10.1016/j.ccell.2021.01.016 PMID 33561397

31. Vergara, I. A., Wilmott, J. S., Long, G. V., Scolyer, R. A. Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape, Exp Dermatol. 2021 Jan 17. doi: 10.1111/exd.14287. Online ahead of print. PMID: 33455025

32. Rabbie, R., Ferguson, P., Wong, K., Couturier, D. L., Moran, U., Turner, C., Emanuel, P., Haas, K., Saunus, J. M., Davidson, M. R., Lakhani, S. R., Shivalingam, B., Long, G. V., Parkinson, C., Osman, I., Scolyer, R. A., Corrie, P., & Adams, D. J. (2020). The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence, Br J Cancer. 2021 Jan;124(1):156-160. doi: 10.1038/s41416-020-01090-2. Epub 2020 Oct 7 PMID 33024263

33. Rogiers, A., Pires da Silva, I., Tentori, C., Tondini, C. A., Grimes, J. M., Trager, M. H., Nahm, S., Zubiri, L., Manos, M., Bowling, P., Elkrief, A., Papneja, N., Vitale, M. G., Rose, A. A. N., Borgers, J. S. W., Roy, S., Mangana, J., Pimentel Muniz, T., Cooksley, T., Lupu, J., Vaisman, A., Saibil, S. D., Butler, M. O., Menzies, A. M., Carlino, M. S., Erdmann, M., Berking, C., Zimmer, L., Schadendorf, D., Pala, L., Queirolo, P., Posch, C., Hauschild, A., Dummer, R., Haanen, J., Blank, C. U., Robert, C., Sullivan, R. J., Ascierto, P. A., Miller, W. H., Jr., Stephen Hodi, F., Suijkerbuijk, K. P. M., Reynolds, K. L., Rahma, O. E., Lorigan, P. C., Carvajal, R. D., Lo, S., Mandala, M., & Long, G. V. (2021). Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition, J Immunother Cancer. 2021 Jan;9(1):e001931. doi: 10.1136/jitc-2020-001931, PMID 33468556

34. Mangantig, E., MacGregor, S., Iles, M. M., Scolyer, R. A., Cust, A. E., Hayward, N. K., Montgomery, G. W., Duffy, D. L., Thompson, J. F., Henders, A., Bowdler, L., Rowe, C., Cadby, G., Mann, G. J., Whiteman, D. C., Long, G. V., Ward, S. V., Khosrotehrani, K., Barrett, J. H., & Law, M. H. (2021). Germline variants are associated with increased primary melanoma tumor thickness at diagnosis. Hum Mol Genet. 2021 Jan 6;29(21):3578-3587. doi: 10.1093/hmg/ddaa222, PMID 33410475

35. Robert, C., Hwu, W. J., Hamid, O., Ribas, A., Weber, J. S., Daud, A. I., Hodi, F. S., Wolchok, J. D., Mitchell, T. C., Hersey, P., Dronca, R., Joseph, R. W., Boutros, C., Min, L., Long, G. V., Schachter, J., Puzanov, I., Dummer, R., Lin, J., Ibrahim, N., Diede, S. J., Carlino, M. S., & Joshua, A. M. (2020). Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma, Eur J Cancer. 2020 Dec 23;144:182-191. doi: 10.1016/j.ejca.2020.11.010. Online ahead of print. PMID 33360855

36. Papadopoulos, K. P., Autio, K. A., Golan, T., Dobrenkov, K., Chartash, E., Chen, Q., Wnek, R., & Long, G. V. (2020). Phase I Study of MK-4166, an Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody, Alone or With Pembrolizumab in Advanced Solid Tumors, Clin


7

Cancer Res. 2020 Dec 21;clincanres.2886.2020. doi: 10.1158/1078-0432.CCR-20-2886. Online ahead of print, PMID 33355238

37. Ferrucci, P. F., Di Giacomo, A. M., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Stephens, R., Svane, I. M., Lotem, M., Abu-Amna, M., Gasal, E., Ghori, R., Diede, S. J., Croydon, E. S., Ribas, A., Ascierto, P. A., & team, K.-i. (2020). KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer, 2020 Dec;8(2):e001806. doi: 10.1136/jitc-2020-001806 PMID: 33361337

38. Hoefsmit EP, Rozeman EA, Van TM, Dimitriadis P, Krijgsman O, Conway JW, Pires da Silva I, van der Wal JE, Ketelaars SLC, Bresser K, Broeks A, Kerkhoven RM, Reeves JW, Warren S, Kvistborg P, Scolyer RA, Kapiteijn EW, Peeper DS, Long GV, Schumacher TNM, Blank CU, Comprehensive analysis of cutaneous and uveal melanoma live metastases, J Immunother Cancer. 2020 Dec;8(2):e001501. doi: 10.1136/jitc-2020-00150, PMID: 33262254

39. Smith AL, Watts CG, Robinson S, Schmid H, Goumas C, Mar VJ, Thompson JF, Rapport F, Australian Melanoma Centre of Research Excellence Study Group*, *Braithwaite J, *Gyorki DE, *Henderson M *Hong AM, *Kelly JW, *Long GV, *Menzies A, *Morton RL, *Saw RPM, *Scolyer RA, *Spillane AJ, *Mann GJ Cust AE, Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study, Australas J Dermatol. 2020 Dec 5. doi: 10.1111/ajd.13518. Online ahead of print. PMID: 33277693

40. Tetzlaff, M. T., Adhikari, C., Lo, S., Rawson, R. V., Amaria, R. N., Menzies, A. M., Wilmott, J. S., Ferguson, P. M., Ross, M. I., Spillane, A. J., Vu, K. A., Ma, J., Ning, J., Haydu, L. E., Saw, R. P. M., Wargo, J. A., Tawbi, H. A., Gershenwald, J. E., Long, G. V., Davies, M. A., & Scolyer, R. A. Histopathologic features of complete pathologic response predict recurrence free survival following neoadjuvant targeted therapy for metastatic melanoma, Ann Oncol. 2020 Nov;30(11):1569-1579. doi: 10.1016/j.annonc.2020.07.016. Epub 2020 Jul 31 PMID: 32739408

41. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, ven den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: new results from the EORTC1325-MG/Keynote 054 trial, J Clin Oncol. 2020 Nov 20;38(33):3925-3936. doi: 10.1200/JCO.20.02110. Epub 2020 Sep 18, PMID32946353

42. Hong, A. M., Waldstein, C., Shivalingam, B., Carlino, M. S., Atkinson, V., Kefford, R. F., McArthur, G. A., Menzies, A. M., Thompson, J. F., & Long, G. V. (2020). Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia, Eur J Cancer, 2020 Nov 15;142:10-17. doi: 10.1016/j.ejca.2020.10.013. Online ahead of print PMID: 33207293

43. Geva, R., Voskoboynik, M., Dobrenkov, K., Mayawala, K., Gwo, J., Wnek, R., Chartash, E., & Long, G. V. (2020). First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors, Cancer. 2020 Nov 15; 126(22):4926-4935. doi: 10.1002/cncr.33133. Epub 2020 Aug 18, PMID 32809217

44. Shklovskaya, E., Lee, J. H., Lim, S. Y., Stewart, A., Pedersen, B., Ferguson, P., Saw, R. P., Thompson, J. F., Shivalingam, B., Carlino, M. S., Scolyer, R. A., Menzies, A. M., Long, G. V., Kefford, R. F., & Rizos, H. (2020). Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma, Cancers, 2020 Nov 14, doi.org/10.3390/cancers12113374 PMID 33202676

45. Nahar KJ, Rawson RV, Ahmed T, Tattersall S, Sandanayake N, Kiely CJ, Lo S, Carlino, Palendira U, Scolyer RA, Long GV, Menzies AM, Clinicopathological characteristics and management of colitis with anti- PD1 immunotherapy alone or in combination with ipilimumab, J Immunother Cancer. 2020 Nov;8(2):e001488. doi: 10.1136/jitc-2020-001488 PMID 33234603

46. Clarke ME, Rizos H, Pereira MR, McEvoy AC, Marsavela G, Calapre L, Mehan K, Ruhen O, Khattak MA, Meiniawy TM, Long GV, Carlino MS, Menzies AM, Millward M, Ziman M, Gray ES, Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies, Oncotarget 2020 Nov 3;11(44):4016-4027. doi: 10.18632/oncotarget.27790, PMID: 33216826


8

47. Dey, A., Manolios, N., Long, G. V., Carlino, M. S., Kefford, R., & Schrieber, L. (2020). Musculoskeletal immune-related adverse events with use of checkpoint inhibitors in malignancy, Intern Med J. 2020 Nov 2. doi: 10.1111/imj.15123. Online ahead of print. PMID: 33135853

48. Dummer, R., Lebbe, C., Atkinson, V., Mandala, M., Nathan, P. D., Arance, A., Richtig, E., Yamazaki, N., Robert, C., Schadendorf, D., Tawbi, H. A., Ascierto, P. A., Ribas, A., Flaherty, K. T., Pakhle, N., Campbell, C. D., Gusenleitner, D., Masood, A., Brase, J. C., Gasal, E., & Long, G. V. (2020). Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i, Nat Med. 2020 Oct;26(10):1557-1563. doi: 10.1038/s41591-020-1082-2. Epub 2020 Oct 5. PMID 33020648

49. Bhave, P., Pallan, L., Long, G. V., Menzies, A. M., Atkinson, V., Cohen, J. V., Sullivan, R. J., Chiarion-Sileni, V., Nyakas, M., Kahler, K., Hauschild, A., Plummer, R., Trojaniello, C., Ascierto, P. A., Zimmer, L., Schadendorf, D., Allayous, C., Lebbe, C., Maurichi, A., Santinami, M., Roy, S., Robert, C., Lesimple, T., Patel, S., Versluis, J. M., Blank, C. U., Khattak, A., Van der Westhuizen, A., Carlino, M. S., Shackleton, M., & Haydon, A. (2020). Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis, Br J Cancer, 2020 Oct 22. doi: 10.1038/s41416-020-01121-y. Online ahead of print. PMID 33087895

50. Newell, F., Wilmott, J. S., Johansson, P. A., Nones, K., Addala, V., Mukhopadhyay, P., Broit, N., Amato, C. M., Van Gulick, R., Kazakoff, S. H., Patch, A. M., Koufariotis, L. T., Lakis, V., Leonard, C., Wood, S., Holmes, O., Xu, Q., Lewis, K., Medina, T., Gonzalez, R., Saw, R. P. M., Spillane, A. J., Stretch, J. R., Rawson, R. V., Ferguson, P. M., Dodds, T. J., Thompson, J. F., Long, G. V., Levesque, M. P., Robinson, W. A., Pearson, J. V., Mann, G. J., Scolyer, R. A., Waddell, N., & Hayward, N. K. (2020). Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020 Oct 16;11(1):5259. doi: 10.1038/s41467-020-18988-3. PMID: 33067454

51. Braun, M., Aguilera, A. R., Sundarrajan, A., Corvino, D., Stannard, K., Krumeich, S., Das, I., Lima, L. G., Meza Guzman, L. G., Li, K., Li, R., Salim, N., Jorge, M. V., Ham, S., Kelly, G., Vari, F., Lepletier, A., Raghavendra, A., Pearson, S., Madore, J., Jacquelin, S., Effern, M., Quine, B., Koufariotis, L. T., Casey, M., Nakamura, K., Seo, E. Y., Holzel, M., Geyer, M., Kristiansen, G., Taheri, T., Ahern, E., Hughes, B. G. M., Wilmott, J. S., Long, G. V., Scolyer, R. A., Batstone, M. D., Landsberg, J., Dietrich, D., Pop, O. T., Flatz, L., Dougall, W. C., Veillette, A., Nicholson, S. E., Moller, A., Johnston, R. J., Martinet, L., Smyth, M. J., & Bald, T. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells, Immunity, 2020 Oct 13, 53(4):805-823.e15. doi: 10.1016/j.immuni.2020.09.010 PMID33053330

52. Fischer, G. M., Carapeto, F. C. L., Joon, A. Y., Haydu, L. E., Chen, H., Wang, F., Van Arnam, J. S., McQuade, J. L., Wani, K., Kirkwood, J. M., Thompson, J. F., Tetzlaff, M. T., Lazar, A. J., Tawbi, H. A., Gershenwald, J. E., Scolyer, R. A., Long, G. V., & Davies, M. A. (2020). Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker, Cancer Med. 2020 Oct 5. doi: 10.1002/cam4.3474. Online ahead of print. PMID 33016647

53. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV. Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. J Clin Oncol. 2020 Sep 30;JCO2000995. doi: 10.1200/JCO.20.00995. Online ahead of print. PMID 32997575

54. Dummer, R., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Kirkwood, J. M., Chiarion Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Lesimple, T., Plummer, R., Dasgupta, K., Gasal, E., Tan, M., Long, G. V*., & Schadendorf, D*. (2020). Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma., N Engl J Med. 2020 Sep 17;383(12):1139-1148. doi: 10.1056/NEJMoa2005493. Epub 2020 Sep 2. PMID: 32877599

55. Attrill, G. H., Ferguson, P. M., Palendira, U., Long, G. V., Wilmott, J. S., & Scolyer, R. A. (2020). The tumour immune landscape and its implications in cutaneous melanoma a, Pigment Cell Melanoma Res, 2020 Sep 16. doi: 0.1111/pcmr.12926 Online ahead of print. PMID 32939993

56. Edwards, J., Ferguson, P. M., Lo, S. N., Pires da Silva, I., Colebatch, A. J., Lee, H., Saw, R. P. M., Thompson, J. F., Menzies, A. M., Long, G. V., Newell, F., Pearson, J. V., Waddell, N., Hayward, N.


9

K., Johansson, P. A., Mann, G. J., Scolyer, R. A., Palendira, U., & Wilmott, J. S. (2020). Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas, Cancer Immunol Res. 2020 Sep 11; canimm.0835.2019. doi: 10.1158/2326-6066.CIR-19-0835. Online ahead of print PMID: 32917657

57. Ascierto, P. A., Puzanov, I., Agarwala, S. S., Blank, C., Carvajal, R. D., Demaria, S., Dummer, R., Ernstoff, M., Ferrone, S., Fox, B. A., Gajewski, T. F., Garbe, C., Hwu, P., Lo, R. S., Long, G. V., Luke, J. J., Osman, I., Postow, M. A., Sullivan, R. J., Taube, J. M., Trinchieri, G., Zarour, H. M., Caraco, C., & Thurin, M. (2020). Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy), 7 Sept 2020, published, DOI: 10.1186/s12967-020-02482-x, PMID: 32894202

58. Hultin, S., Nahar, K., Menzies, A. M., Long, G. V., Fernando, S. L., Atkinson, V., Cebon, J., & Wong, M. G. (2020). Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report, BMC Nephrology, 7 Sept 2020, DOI: 10.1186/s12882-020-02044-9, PMID: 32894101

59. Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, Mangana J, Atkinson V, Zaman F, Young A, Hoeller C, Hersey P, Dummer R, Khattak MA, Millward M, Patel SP, Haydon A, Johnson DB, Lo S, Blank CU, Sandhu S, Carlino MS, Larkin JMG, Menzies AM*, Long GV* Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy, Ann Oncol 2020 Aug;31(8):1075-1082. doi: 10.1016/j.annonc.2020.04.471. Epub 2020 May 6. PMID: 32387454

60. Diefenbach, R. J., Lee, J. H., Menzies, A. M., Carlino, M. S., Long, G. V., Saw, R. P. M., Howle, J. R., Spillane, A. J., Scolyer, R. A., Kefford, R. F., & Rizos, H. (2020). Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA, Cancers (Basel) 2020 Aug 10;12(8):E2228. doi: 10.3390/cancers12082228, PMID 32785074

61. Puzanov I, Ribas A, Robert C, Schachter J, Nyakas N, Daud A, Blank CU, Arance A, Carlino MS, O’Day SJ, Long GV, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Moreno BH, Ibrahim N. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. JAMA Oncol. 2020 Aug 1;6(8):1256-1264. doi: 10.1001/jamaoncol.2020.2288. PMID 32672795

62. Menzies AM, Carlino MS, McEvoy AC, Sandhu A, Weppler AM, Diefenback RJ, Dawson SJ, Kefford RF, Millward MJ, Al-Ogaili S, Tra T, Gray ES, Wong SQ, Scolyer RA, Long GV, Rizos H. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. Clin Cancer Res. 2020 Aug 1;26(15):4064-4071. doi: 10.1158/1078-0432.CCR-19-3926. Epub 2020 Apr 22. PMID 3231716

63. Puzanov, I., Ribas, A., Robert, C., Schachter, J., Nyakas, M., Daud, A., Arance, A., Carlino, M. S., O'Day, S. J., Long, G. V., Margolin, K. A., Dummer, R., Schadendorf, D., Lutzky, J., Ascierto, P. A., Tarhini, A., Lin, J., Mogg, R., Homet Moreno, B., Ibrahim, N., & Hamid, O. (2020). Association of BRAFV600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of Three Clinical Trials JAMA Oncol. 2020 Aug 1;6(8):1256-1264. doi: 10.1001/jamaoncol.2020.2288, PMID: 32672795

64. SC. Sasson*, JJ. Zaunders, K. Nahar, C. Mee-Ling Munier, BP. Fairfax, S. Danielli, A. Olsson-Brown, Cc Jolly, SA. Read, G, Ahlenstiel, U. Palendira, RA. Scolyer, MS. Carlino, MJ. Payne, VTF. Cheung, T. Gupta, P Klenerman, GV. Long, O. Brain#, AM. Menzies, AD. Kelleher# Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis, Clin Exp Immunol. 2020 Jul 31. doi: 10.1111/cei.13502. Online ahead of print PMID: 32734627

65. Khushalani, N. I., Diab, A., Ascierto, P. A., Larkin, J., Sandhu, S., Sznol, M., Koon, H. B., Jarkowski, A., Zhou, M., Statkevich, P., Geese, W. J., & Long, G. V. (2020). Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design, Future Oncol. 2020 Jul 29. doi: 10.2217/fon-2020-0351. Online ahead of print. PMID: 32723187

66. Grossman D, Bar-Eli M,. Bartlett EK, Berry E, Berwick M, Bowen GM, Bowles T, Buchbinder EI, Burton E, Chu EY,. Coit DG, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon D, Ferris LK, Gershenwald JE, Grossmann KF, Hartman RI, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres R, Karakousis GC, Kendra KL, Korde L, Lawson DH, Leachman SA, Lee S, Leming PD, Long GV,


10

Kim CC, Kirkwood JM, Marchetti MA, Mehnert JM, Ming ME, Nelson KC, Okwundu N, Othus M, Polsky D, Scolyer RA, Smith EA, Sondak V, Stark M, Thompson JA, Thompson JF, Wei ML, Swetter SM. Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit. JAMA Dermatology 29 July 2020 DOI: 10.1001/jamadermatol.2020.1729 PMID: 32725204

67. MH Law, LG Aoude, DL Duffy, GV Long, PA Johannson, AL Pritchard, K Khosrotehani, GJ Mann, GW Montgomery, MM Iles, AE Cust, J Palmer, Melanoma GWAS Consortium, KF Shannon, AJ Spillane, JR Stretch, JF Thompson, RPM Saw, RA Scolyer, NG Martin, NK Hayward, S MacGregor Multiplex melanoma families are enriched for polygenic risk colour figures : Yes, Hum Mol Genet. 2020 Jul 27;ddaa156. doi: 10.1093/hmg/ddaa156. Online ahead of print

68. Barnhill R, van Dam PJ, Vermeulen P, Champenois G, Nicolas A, Rawson RV, Wilmott JS, Thompson JF, Long GV, Cassoux N, Roman-Roman S, Busam KJ, Scolyer RA, Lazar AJ, Lugassy C. Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value, J Pathol Clin Research, 2020 Jul;6 (3):195-206. doi: 10.1002/cjp2.161. Epub 2020 Apr 18, PMID: 32304183

69. Carlino, M. S., Menzies, A. M., Atkinson, V., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., Hwu, W. J., Hodi, F. S., Guminski, A. D., Kefford, R., Wu, H., Ibrahim, N., Homet Moreno, B., & Long, G. V. (2020). Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B Clin Cancer Res, 2020 Jun 30. doi: 10.1158/1078-0432.CCR-20-0177. Online ahead of print. PMID 32605909.

70. Gide T, Silva IP, Quek C, Ahmed T, Menzies AM, Carlino MS, Saw RPM, Thompson JF, Batten M, Long GV, Scolyer RA, Wilmott JS. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. Oncoimmunology. 2019 Oct 16;9(1):1659093. doi: 10.1080/2162402X.2019.1659093. PMID32002281

71. GV Long and RA Scolyer. Translating Basic Cancer Discoveries to the Clinic. Feature Article: A Critical Nexus. Cancer cell, 8 June 2020, Vol.37(6), pp.735-737. DOI:https://doi.org/10.1016/j.ccell.2020.05.017. PMID: 32516583

72. Cipponi A, Goode DL, Bedo J, Croucher DR, McCabe MJ, Rajal AG, Saunders DN, Lobachevsky P, Junanakar SR, Papenfuss AT, Pajic M, Nessen D, Nobis M, Warren SC, Timpson P, Cowley M, Vargas AC, Qiu MR, Generali DG, Keerthikumar S, Nguyen U, Corcoran NM, Long GV, Blay LY, Thomas DM. MTOR Signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancers. Science. 2020 Jun 5;368(6495):1127-1131. doi: 10.1126/science.aau8768. PMID 32499442

73. Watts, C. G., Smith, A. L., Robinson, S., Chang, C. S., Goumas, C., Schmid, H., Kelly, J. W., Hong, A. M., Scolyer, R. A., Long, G. V., Spillane, A. J., Henderson, M., Gyorki, D. E., Mar, V. J., Morton, R. L., Saw, R. P., Varey, A. H., Mann, G. J., Thompson, J. F., Cust, A. E., Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management, Aust J Gen Pract, 2020 Jun;4 9(6):355-362. doi: 10.31128/AJGP-10-19-5138. PMID: 32464734

74. Tsang V, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, Long GV, Menzies AM, Response to Letter to the Editor for “Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes”. J Clin Endocrinol Metab. 2020 Jun 1;105(6). pii: dgaa144. doi: 10.1210/clinem/dgaa144. PMID 32188993.

75. Tsang VHM, McGrath RT, Clifton-Bligh RJ, Jakrot V, Scolyer RA, Guminski AD, Long GV, Menzies AM. Response to Letter to the Editor: “Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes”.. J Clin Endocrinol Metab. 2020 Jun 1;105(6). pii: dgaa144. doi: 10.1210/clinem/dgaa144. PMID32188993

76. Johansson, P. A., Brooks, K., Newell, F., Palmer, J. M., Wilmott, J. S., Pritchard, A. L., Broit, N., Wood, S., Carlino, M. S., Leonard, C., Koufariotis, L. T., Nathan, V., Beasley, A. B., Howlie, M., Dawson, R., Rizos, H., Schmidt, C. W., Long, G. V., Hamilton, H., Kiilgaard, J. F., Isaacs, T., Gray, E. S., Rolfe, O. J., Park, J. J., Stark, A., Mann, G. J., Scolyer, R. A., Pearson, J. V., van Baren, N., Waddell, N., Wadt, K. W., McGrath, L. A., Warrier, S. K., Glasson, W., & Hayward, N. K. (2020). Whole genome landscapes of uveal melanoma show a role for ultraviolet radiation in iris tumours, Nature Communications, 2020 May 15;11(1):2408. doi: 10.1038/s41467-020-16276-8, PMID: 32415113


11

77. Siemys A, Kim MS, Menzies A, Willmott J, Long GV, Scolyer RA, Kwong LN, Holder AM, Boland GM. Integration of Digital Pathologic and Transcriptomic Analyses Connect Tumor-Infiltrating Lymphocyte Spatial Density with Clinical Response to BRAF Inhibitors. Frontiers in Oncology 2020 May 14;10:757. doi: 10.3389/fonc.2020.00757. eCollection 2020, PMID: 32528881

78. Ugurel S, Röhmel J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Livingstone E, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Zimmer L, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition – Update 2019 - Eur J Cancer. 2020 May;13 0:126-138. doi: 10.1016/j.ejca.2020.02.021. Epub 2020 Mar 13, PMID 32179447

79. Landi MT, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, Brossard M, Calista D, Choi J, Fargnoli MC, Zhang T, Rodolfo M, Trower AJ, Menin C, Martinez J, Hadjisavvas A, Song L, Stefanaki I, Scolyer R, Yang R, Goldstein AM, Potrony M, Kypreou KP, Pastorino L, Queirolo P, Pellegrini C, Cattaneo L, Zawistowski M, Gimenez-Xavier P, Rodriguez A, Elefanti L, Manoukian S, Rivoltini L, Smith BH, Loizidou MA, Del Regno L, Massi D, Mandala M, Khosrotehrani K, Akslen LA, Amos CI, Andresen PA, Avril MF, Azizi E, Soyer HP, Bataille V, Dalmasso B, Bowdler LM, Burdon KP, Chen WV, Codd V, Craig JE, Dębniak T, Falchi M, Fang S, Friedman E, Simi S, Galan P, Garcia-Casado Z, Gillanders EM, Gordon S, Green A, Gruis NA, Hansson J, Harland M, Harris J, Helsing P, Henders A, Hočevar M, Höiom V, Hunter D, Ingvar C, Kumar R, Lang J, Lathrop GM, Lee JE, Li X, Lubiński J, Mackie RM, Malt M, Malvehy J, McAloney K, Mohamdi H, Molven A, Moses EK, Neale RE, Novaković S, Nyholt DR, Olsson H, Orr N, Fritsche LG, Puig-Butille JA, Qureshi AA, Radford-Smith GL, Randerson-Moor J, Requena C, Rowe C, Samani NJ, Sanna M, Schadendorf D, Schulze HJ, Simms LA, Smithers M, Song F, Swerdlow AJ, van der Stoep N, Kukutsch NA, Visconti A, Wallace L, Ward SV, Wheeler L, Sturm RA, Hutchinson A, Jones K, Malasky M, Vogt A, Zhou W, Pooley KA, Elder DE, Han J, Hicks B, Hayward NK, Kanetsky PA, Brummett C, Montgomery GW, Olsen CM, Hayward C, Dunning AM, Martin NG, Evangelou E, Mann GJ, Long GV, Pharoah PDP, Easton DF, Barrett JH, Cust AE, Abecasis G, Duffy DL, Whiteman DC, Gogas H, De Nicolo A, Tucker MA, Newton-Bishop JA; GenoMEL Consortium; Q-MEGA and QTWIN Investigators; ATHENS Melanoma Study Group; 23andMe; SDH Study Group; IBD Investigators; Essen-Heidelberg Investigators; AMFS Investigators; MelaNostrum Consortium, Peris K, Chanock SJ, Demenais F, Brown KM, Puig S, Nagore E, Shi J, Iles MM, Law MH. Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility. Nat Genet. 2020 May;52(5):494-504. doi: 10.1038/s41588-020-0611-8. Epub 2020 Apr 27 PMID:32341527

80. Haydu LE, Lo S, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza I, Tawbi H, Carlino MS, Menzies AMM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma J Clin Oncol. 2020 May 1;38(13):1429-1441. doi: 10.1200/JCO.19.01508. Epub 2020 Jan 28, PMID31990608

81. Lepletier A, Madore J,O’Donnell JS, Johnston RL, Li XY, McDonald E, Ahern E, Kuchel A, Eastgate M, Pearson SA, Mallardo D, Ascierto PA, Massi D, Merelli B, Mandala M, Willmott JS, Menzies AM, Leduc C, Stagg J, Routy B, Long GV, Scolyer RA, Bald T, Waddell N, Dougall WC, Teng MWL. Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. Clin Cancer Res. 28 Apr 2020. pii: clincanres.3925.2019. doi: 10.1158/1078-0432.CCR-19-3925. PMID: 32345648

82. Versluis JM, Long GV, Blank CU. Learning from Clinical Trials of neoadjuvant checkpoint blockade. Nature Medicine Published 26 April 2020. 10.1038/s41591-020-0829-0. PMID 32273608

83. Lee JH, Menzies AM, Carlino MS, Mcevoy AC, Sandhu S, Weppler AM, Diefenbach RJ, Dawson SJ, Kefford RF, Millward MJ, Al-Ogaili S, Tra T, Gray ES, Wong SQ, Scolyer RS, Long GV, Rizos H. Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors. 22 April 2020 Clin Cancer Res. doi: 10.1158/1078-0432.CCR-19-3926 PMID 32321716

84. Lee J, Shklovskaya E, Yin Lim S , Carlino M, Menzies A, Stewart A, Pedersen B, Irvine M, Alavi S, Yang J, Strbenac D, Saw R, Thompson J, Wilmott J, Scolyer R, Long GV, Kefford R, Rizos H.


12

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nat Commun. 2020 Apr 20;11(1):1897. doi: 10.1038/s41467-020-15726-7. PMID 32312968

85. McKelvey, K. J., Hudson, A. L., Prasanna Kumar, R., Wilmott, J. S., Attrill, G. H., Long, G. V., Scolyer, R. A., Clarke, S. J., Wheeler, H. R., Diakos, C. I., & Howell, V. M. (2020). Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model. PLoS One. 2020 Apr 2;15(4):e0226444. doi: 10.1371/journal.pone.0226444. PMID 32240177

86. Wang DY, McQuade JL; Rai RR, Park JJ, Zhao S, Ye F, Beckermann KE, Rubinstein SM; Johnpulle RA, Long GV, Carlino MS, Menzies AM, Davies MA, Johnson DB. The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. The Oncologist 2020 Mar;25(3):e602-e605. doi: 10.1634/theoncologist.2019-0518. Epub 2019 Nov 29 PMID: 32162820

87. Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood JM, Hauschild A, Schadendorf D, Long GV. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Onc. Lancet Oncol. 2020 Mar;21(3):358-372. doi: 10.1016/S1470-2045(20)30062-0. PMID32007138

88. Pirozyan MR, McGuire HM, Al Emran A, Tseng H, Tiffen JC, Lee JH, Carlino MS, Menzies AM, Long GV, Scolyer RA, Fazekas de St Groth B, Hersey P. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. Front Immunol. 2020 Mar 10; 11:372. doi: 10.3389/fimmu.2020.00372. PMID 32210968

89. Rapport F, Smith AL, Cust AE, Mann GJ, Watts CG, Gyorki DE, Henderson M, Hong AM, Kelly JW, Long GV, Mar VJ, Morton RL, Saw RP, Scolyer RA, Spillane AJ, Thompson JF, Braithwaite J. Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. 27 Feb 2020 BMJ Open. doi: 10.1136/bmjopen-2019-032636. PMID 32111612

90. Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV Atkinson V, Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial, JAMA Oncol, 2 Jan 2020 doi: 10.1001/jamaoncol.2019.5570. PMID 31895407

91. Luke J, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, Eggermont AMM. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. E-published 24 December 2019, 16(3), 4429–4438. DOI: 10.2217/fon-2019-0666, PMID: 31870188

92. Diefenbach, R. J., Lee, J. H., Strbenac, D., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Long, G. V., Spillane, A. J., Stretch, J. R., Saw, R. P. M., Thompson, J. F., Ch'ng, S., Scolyer, R. A., Kefford, R. F., & Rizos, H. (2019). Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. Cancers (Basel). 2019 Nov 29;11(12). pii: E1905. doi: 10.3390/cancers11121905. PMID 31795494

93. Atkinson V, Sandhu S, Hospers G, Long GV, Aglietta M, Ferrucci PF, Tulyte S, Cappellini GCA, Soriano V, Sayed Ali, Poprach A, Cesas A, Rodriguez-Abreu D, Lau M, de Jong E, Legenne P, Stein D, King B, van Thienen JV. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). EPub ahead of print. Melanoma Res. 2020 Jun;30, doi: 10.1097/CMR.0000000000000654. PMID31895752

94. Diefenbach RJ, Lee JH, Chandler D, Wang Y, Pflueger C, Long GV, Scolyer RA, Carlino MS, Menzies AMM, Kefford RF, Rizos H. Hypermethylation of Circulating Free DNA in Cutaneous Melanoma. Applied sciences. 2019,


13

95. Hong AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, Lo SN, Haydu LE, Vardy JL, Nowak AK, Dhillon HM, Ahmed T, Shivalingam B, Long GV, Menzies AM, Hruby G, Drummond KJ, Mandel C, Middleton MR, Reisse CH, Paton EJ, Steel V, Williams NC, Scolyer RA, Morton RL, Thompson JF. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2019 Nov 20;37(33):3132-3141. doi: 10.1200/JCO.19.01414. PMID31553661

96. Silva I, Lo S, Quek C, Gonzalez M, Carlino MS, Long GV, Menzies AM. Site-Specific Response Patterns, Pseudoprogression, and Acquired Resistance in Patients With Melanoma Treated With Ipilimumab Combined With Anti–PD-1 Therapy. Cancer. 2020 Jan 1;126(1):86-97. doi: 10.1002/cncr.32522. PMID31584722

97. House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, Sek K, Mardiana S, Gide TN, Quek C, Scolyer RA, Long GV, Wilmott JS, Loi S, Darcy PK, Beavis PA. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clin Cancer Res. 2020 Jan 15;26(2):487-504. doi: 10.1158/1078-0432.CCR-19-1868. PMID31636098

98. Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms K, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC. Targeted therapy in advanced melanoma with rare BRAF mutations. J Clin Oncol. 2019 Nov 20;37(33):3142-3151. doi: 10.1200/JCO.19.0048. PMID31580757.

99. Mason R, Dearden HC, Nguyen B, Oon JS, Smith JL, Randhawa M, Mant A, Warburton L, Lo S, Meniawy T, Guminski A, Parente P, Ali S, Haydon A, Long GV, Carlino MS, Millward M, Atkinson VG, Menzies AM. Combined ipilimumab and nivolumab first-line and after BRAF targeted therapy in advanced melanoma. Pigment Cell Melanoma Res. 2020 Mar;33(2):358-365. doi: 10.1111/pcmr.12831. PMID31587511.

100. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao CD, Cowey L, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi S, Wolchok JD. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. PMID31562797.

101. Long GV, Saw RPM, Lo S, Nieweg OE, Shannon KF, Gonzalez M, Guminski A, Lee JH, Lee H, Ferguson PM, Rawson RV, Wilmott JS, Thompson JF, Kefford RF, Ch’ng S, Stretch JR, Emmett L, Kapoor R, Rizos H, Spillane AJ, Scolyer RA, Menzies AM. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 2019 Jul;20(7):961-971. doi: 10.1016/S1470-2045(19)30331-6 . PMID31171444

102. Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. PMID31221619

103. Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., Gogas, H., Mandala, M., Haanen, J., Lebbe, C., Mackiewicz, A., Rutkowski, P., Nathan, P. D., Ribas, A., Davies, M. A., Flaherty, K. T., Burgess, P., Tan, M., Gasal, E., Voi, M., Schadendorf, D., & Long, G. V. (2019). Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma, N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4, PMID: 31166680

104. Colebatch AJ, Ferguson P, Newell F, Kazakoff S, Witkowski T, Dobrovic A, Johansson PA, Menzies AM, Saw R, Stretch J, McArthur G, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Waddell N, Scolyer RA, Wilmott JS. Molecular genomic profiling of melanocytic nevi. J Invest Dermatol. 2019 Aug;13. doi: 10.1016/j.jid.2018.12.033. Epub 2019 Feb 14. PMID 30772300


14

105. Newel F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Liang Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, Jönsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane A, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun. 2019 Jul 18;10(1):3163. doi: 10.1038/s41467-019-11107. PMID31320640

106. Zhang X, Zhong Tang J, Vergara I, Fang Zhang Y, Szeto P, Yang L, Mintoff C, Colebatch A, Mcintosh L, Mitchell K, Shaw E, Rizos H, Long GV, Hayward N, McArthur G, Papenfuss A, Harvey K, Shackleton M. Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma. Mol Cancer Res 2018. Mol Cancer Res. 2019 Jul;17(7):1435-1449. doi: 10.1158/1541-7786.MCR-18-0407. Epub 2019 Mar 4. PMID 30833299

107. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert, C. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. PMID31200321

108. Ascierto PA, Ferrucci PF, Fisher R Del Vecchio, M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019 Jun;25(6):941-946. doi: 10.1038/s41591-019-0448-9. Epub 2019 Jun 6 PMID: 31171878

109. Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019; 20(9):1239-1251

110. Johnson DB, McDonnell WJ, Ericsson-Gonzalez PI, Al-Rohil R, Mobley BC, Salem J-E, Wang DY, Sanchez V, Wang Y, Chastain CA, Barker K, Liang Y, Warren S, Beechem J, Menzies AM, Tio M, Long GV, Cohen JV, Guidon AC, O’Hare M, Chandra S, Chowdhary A, Lebrun-Vignes B, Goldinger S, Rushing E, Buchbinder E, Mallal SA, Shi C, Xu Y, Moslehi JJ, Sanders ME, Sosman JA, Balko JM. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Med 2019; 25(8):1243-1250.

111. Ipenburg NA, Nieweg O, Ahmed T, van Doorn R, Scolyer RA, Long GV, Thompson JF, Lo S. External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma, . Br J Surg. 2019 Sep;10 6(10):1319-1326. doi: 10.1002/bjs.11262. Epub 2019 Jul 16, PMID: 31310333

112. Amaria RN, Menzies A, Burton EM, Van Akooi A, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty K, Gershenwald JE, Hamid O, Hong A, Kirkwood J, Lo S, Margolin K, Messina J, Postow M, Rizos H, Ross MI, Rozeman L, Saw R, Scolyer R, Sondak V, Spillane A, Sullivan RJ, Taube J, Tetzlaff MT, Thompson J, Van de Weil B, Davies JMA, Wargo JA, Blank CU, Tawbi H, Long GV. Shaping the Future of Neoadjuvant Systemic Therapy in Melanoma: Recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Onocology. Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8 PMID 31267972

113. Long GV, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Hauschild A. Reply to E. Hindié and K.R. Hess. J Clin Oncol. 2019 May 20;37(15):1356-1358. doi: 10.1200/JCO.19.00004. Epub 2019 Apr 2. PMID 30939092


15

114. Gide, T. N., Allanson, B. M., Menzies, A. M., Ferguson, P. M., Madore, J., Saw, R. P. M., Thompson, J. F., Long, G. V., Wilmott, J. S., & Scolyer, R. A. (2019). Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. Histopathology. 2019 May;74(6):817-828. doi: 10.1111/his.13814, PMID: 30589949

115. Long GV. Making a difference to many. Nat Med. March 2019;25(3):356.

116. Long GV, Gasal E, Hauschild A. Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. Reply. N Engl J Med. April 2019;380(14):1376-7.

117. Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejbergs L, Schmidt H, van Thiene JV, Haanen Jbag, Tiainen L, Svane IM, Makela S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. March 2019.

118. Mittal D, Lepletier A, Madore J, Aguilera AR, Stannard K, Blake SJ, Whitehall, V L J, Liu C, Bettington M. L, Takeda K, Long GV, Scolyer R. A, Lan R, Siemers N, Korman A, Teng MWL, Johnston R. J, Dougall WC, Smyth, M J. CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. Cancer Immunol Res. 2019 Apr;7(4):559-571. doi: 10.1158/2326-6066.CIR-18-0637. Epub 2019 Mar 20. PMID: 30894377

119. Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., Broeks, A., van Thienen, J. V., Guminski, A. D., Acosta, A. T., Ter Meulen, S., Koenen, A. M., Bosch, L. J. W., Shannon, K., Pronk, L. M., Gonzalez, M., Ch'ng, S., Grijpink-Ongering, L. G., Stretch, J., Heijmink, S., van Tinteren, H., Haanen, J., Nieweg, O. E., Klop, W. M. C., Zuur, C. L., Saw, R. P. M., van Houdt, W. J., Peeper, D. S., Spillane, A. J., Hansson, J., Schumacher, T. N., Long, G. V., & Blank, C. U. (2019). Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31. PMID: 31160251

120. Quek C, Rawson RV, Ferguson PM, Shang P, Silva I, Saw RPM, Shannon K, Thompson JF, Hayward NK, Long GV, Mann GJ, Scolyer RA, Wilmott JS. Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget. Jan 2019;10(9):930-41.

121. Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SM, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM., Long GV, Johnson DB, Menzies AM. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell Melanoma Res. 2019. 32(4):553-563

122. Heinzerling L, Ascierto PA; Dummer R, GogasH, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A. Adverse events 2.0- Let's get SERIOs New reporting for adverse event outcomes needed in the era of immunooncology. Eur J Cancer. 2019 May;112:29-31. doi: 10.1016/j.ejca.2019.01.015. Epub 2019 Mar 21. PMID: 30903870

123. Edwards J, Batten M, Ferguson A, Palendira U, Wilmott JS, Long GV, Scolyer RA. Novel immune targets in melanoma – Response. Clin Cancer Res Sept 2019. 25:5254-5425.

124. Edwards JJ, Tasker A, Silva I, Quek C, Batten M, Ferguson AL, Allen R, Allanson BM, Saw RP, Thompson JF, Menzies AM, Palendira U, Wilmott JS, Long GV, Scolyer RA. Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naive melanoma: implications for clinical trials. Clin Cancer Res. June 2019. 25:3247-3258.

125. Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH, Jr, Carlino MS, Fisher R, Long GV, Hodi SF, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Homet Moreno B, Ibrahim N, Hamid O. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. 2019 Nature Medicine. 25:936-940


16

126. Lee JH, Saw RPM, Thompson JF, Lo S, Spillane AJ, Shannon KF, Stretch J, Howle J, Menzies AM, Carlino MS, Kefford RF, Long GV, Scolyer RA, Rizos. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients Annals of Oncology. 2018 30:815-822.

127. Kim H, Duong JK, Gonzalez M, Long GV, Menzies AM, Rizos H, Yin Lim S, Lee J, Boddy AV. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. Cancer Chemother Pharmacol April 2019. 83:693-704.

128. Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Lesimple, T., Plummer, R., Schachter, J., Dasgupta, K., Manson, S., Koruth, R., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M., & Long, G. V. (2019). Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 May;20(5):701-710. doi: 10.1016/S1470-2045(18)30940-9. Epub 2019 Mar 27, PMID: 30928620

129. Gide T, Quek C, Menzies A, Tasker A, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RP, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva I, Batten M, Scolyer RA, Wilmott JS* Long GV*,. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell Feb 2019. 35: 238-255.

130. Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles , Mihalcioiu C, Chiarion-Sileni V,Mauch C, Cognetti F, Ny L,Arance A, Marie Svane I, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V. Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Onc 2018. [Epub ahead of print].

131. Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood J, Long GV. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol 2018. [Epub ahead of print].

132. Arasaratnam M, Hong A, Shivalingam B, Wheeler H, Guminksi A, Long GV, Menzies AM. Leptomeningeal melanoma-A case series in the era of modern systemic therapy. Pigment Cell Melanoma Res 2018; 31: 120-124.

133. Lim S, Lee J, Gide T, Menzies A, Guminski A, Carlino M, Breen E, Yang J, Ghazanfar S, Kefford R, Scolyer R, Long GV, Rizos H. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. Clin Cancer Res. 2019 Mar 1;25(5):1557-1563. doi: 10.1158/1078-0432.CCR-18-2795. Epub 2018 Nov 8. 3, PMID: 30409824

134. Pires da Silva I, Wang K, Wilmott J, Holst J, Carlino M, Park J, Quek C, Wongchenko M, Yan Y, Mann G, Johnson D, McQuade J, Rai R, Kefford R, Rizos H, Scolyer R, Yang J, Long GV, Menzies A. Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma. Clin Cancer Res 2019; 25: 1272-1279

135. Lee H, Quek C, Edwards J, Madore J, Palendira M, Menzies A, Carlino M, Guminski A, Saw R, Thompson J, Silva I, Ferguson P, Long GV, Scolyer R, Wilmott J. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. Oncoimmunology 2019, 8: e1537581

136. Tio M, Rai R, Ezeoke OM, McQuade J, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson B, Rizvi H, Joshua AM, Hellmann MD, Long GV, Menzies AM. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur J Cancer 2018; 104: 137-144.

137. Orozco J, Knijnenburg J, Manughian-Peter A, Salomon M, Barkhoudarian G, Jalas J, Wilmott J, Hothi, Xiaowen Wang R, Takasumi Y, Buckland M, Thompson J, Long GV, Cobbs C, Shmulevich I, Kelly


17

D, Scolyer R, Hoon D, Marzese D. Epigenetic profiling for the molecular classification of metastatic brain tumors. Nature Communications 2018; 9: 4627.

138. Wang D, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell K, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan R, Moslehi JJ, Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923, PMID: 30242316

139. Dodds T, Wilmott J, Jackett L, Lo S, Long GV, Thompson J, Scolyer R. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. Pathology 2019. Epub; 51: 39-45.

140. Silva da I, Battem M, Long GV. Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas. Br J Cancer 2018; 119: 661-662.

141. Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol 2018. 29:2208-2213.

142. Wang K, Menzies AM, Silva IP, Wilmott J, Yan Y, Wongchenko M, Kefford R, Scolyer RA, Long GV, Tarr G, Mueller S, Yang JYH. bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. Bioinformatics. 2019 Apr 15;35(8):1350-1357. doi: 10.1093/bioinformatics/bty783. PMID: 30215668

143. Allanson B, Weber M, Jackett L, Chan C, Lau L, Ziegler D, Warby M, Long GV, Maher A, Tucker K, Anazodo A, Scolyer RA. Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. Pathology 2018. 50: 648-653.

144. Wilmott J, Johansson P, Newell F, Waddell N, Ferguson P, Quek C, Patch AM, Nones K, Shang P, Pritchard A, Kazakoff S, Holmes O, Leonard C, Wood S, Xu Q, Saw RP, Spillane AJ, Stretch JR, Shannon KF, Kefford RF, Menzies AM, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA. Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. Int J Cancer 2019; 144: 1049-1060.

145. Strub T, Ghiraldini F, Carcamo S, Wroblewska A, Li M, Wang Z, Singh R, Goldberg M, Hasson D, Gallagher S, Hersey P, Ma'ayan A, Long GV, Scolyer R, Zheng B, Brown B, Bernstein E. SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signaling. Nat Commun 2018; 9:3440.

146. Krisp C, Parker R, Pascovici D, Hayward NK, Wilmott JS, Thompson JF, Mann G, Long GV, Scolyer R, Molloy M. Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. Br J Cancer 2018; 119: 713-723.

147. Tetzlaff M, Messina J, Stein J, Xu X, Amaria R, Blank C, Van De Wiel B, Ferguson P, Rawson R, Ross M, Spillane A, Gershenwald J, Saw R, Mitchell T, Menzies A, Long GV, Wargo J, Davies M, Prieto V , Taube J, Scolyer R. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol 2018; 29: 1861-1868.

148. Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blan C, Hoeller C, Bar-Selat G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N , Daud A. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomized clinical trial. Eur J Cancer 2018; 101: 236-243.

149. Long GV, Atkinson V, Hong A, McArthur G, Menzies AM. Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - Authors' reply. Lancet Oncol 2018; 19: e367.

150. Eggermont A, Blank C, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, LichinitserM, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto P, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh A, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi A, Suciu S, Robert C. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med 2018; 378: 1789-1801.


18

151. Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss S, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea G, Ecker BL, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich DI, Stone EL, Nowicki TS, Sosman JA, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies11, Schilling MA, Schadendorf D, Menzies AM, McQuade JL, Johnson DB, Osman, Weeraratna1 AT. Age correlates with response to anti-PD1, reflecting age-related differences in intra-tumoral effector and regulatory T cell populations. Clinical Cancer Res. 2018; 24: 5347-5356.

152. Long GV, Hauschild A, Kirkwood M. Adjuvant Therapy in Resected Melanoma.. N Engl J Med 2018; 19:1813-1823.

153. Edwards J, Wilmott J, Madore J, Gide T, Quek C, Chen J, Hewavisenti R, Hersey P, Gebhardt T, Weninger W, Britton W, Saw R, Thompson J, Menzies A, Long GV, Scolyer R, Palendira U. CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy naive melanoma patients and response to anti-PD1 immunotherapy. Clin Cancer Res 2018; 24: 3036-3045.

154. Borcoman E, Nandikolla A, Long GV, Goel S, Le Tourneau C. Patterns of response and progression to immunotherapy. American Society for Clinical Oncology Education Book 2018. 38:169-178.

155. Long GV, Atkinson V, Lo S, Guminski AS, Sandhu S, Brown MP, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018; 19:672-681.

156. De Sousa SMC, Sheriff N, Tran CH, Menzies AM, Tsang VHM, Guminksi AD, Long GV, Tonks KTT. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary 2018; 21: 274-282.

157. Star P, Goodwin A, Kapoor R, Conway RM, Long GV, Scolyer R, Guitera P. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. Eur J Cancer 2018; 92: 48-53.

158. Tio M, Xuan W, Carlino, Shivalingam B, Fogarty G, Guminski A, Lo S, Hong A, Menzies A, Long GV. Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. Pig Cell Mel Res 2017; 31:509-515.

159. Valpione S, Carlino MS, Mangana J, Mooradian MJ,McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J,Park JJ, Goldinger S, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P. Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" Eur J Cancer 2018; 91: 116-124.

160. Lee J, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford K, Rizos H, Carlino M. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncol 2018; 4: 717-721.

161. Scott E, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang V. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma Eur J Endocrinol 2018; 178: 175-182.

162. Tan A, Emmett L, Lo S, Liu V, Kapoor R, Carlino M, Guminski A, Long GV, Menzies A. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol 2018; 29: 2115-2120.

163. McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JP, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki T, Avila A , Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol 2018; 19: 310-322.


19

164. Lee J, Lyle M, Menzies A, Chan M, Lo S, Clements A, Carlino M, Kefford R, Long GV. Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. Pigment Cell Melanoma Res 2018; 31: 404-410.

165. Long GV. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma. Clin Adv Hematol Oncol 2018; 16(1):25-27.

166. Ferguson P, Long GV, Scolyer RA, Thompson JF. Impact of genomics on the surgical management of melanoma. Br J Surg 2018; 105: e31-e47.

167. Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 2018; 29: 250-255.

168. Liang R, Meiser B, Smith S, Kasparian N, Lewis C, Chin M, Long GV, Ward R, Menzies A, Harris-Wai J, Kaur R. Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study. Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12600. Epub 2016 Oct 11

169. Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V. , Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., Haydu, L. E., Eggermont, A. M. M., Flaherty, K. T., Balch, C. M., Thompson, J. F. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin. 2017 Nov;6 7(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13, PMID: 29028110

170. Arasaratnam M, Hong A, Shivalingam B, Wheeler H, Guminski A, Long GV, Menzies AM. Leptomeningeal melanoma – a case series in the era of modern systemic therapy. Pig Cell Mel Res 2017. 31:120-124.

171. Davies MA, Saiag P, Long GV. Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough? - Authors' reply. Lancet Oncol 2017; 18:509.

172. Gu YF, Menzies AM, Long GV, Fernando SL, Herkes G. Immune mediated neuropathy following combined checkpoint immunotherapy. J Clin Neurosci 2017; 45:14-17.

173. Gide TN, Wilmott J, Scolyer R, Long GV. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clin Cancer Res 2018; 24: 1260-1270.

174. Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Won Kim D, Algazi A, Johnson DB, Liniker E, Kong B, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku P, Wei C, Sosman JA, Joseph R, Postow MA, Carlino MS, Hwu W-J, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A. High response rate to PD-1 blockade in desmoplastic melanomas. Nature 2018; 553: 347-350.

175. Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J Clin Oncol 2018; 36: 667-673.

176. Long GV, Hauschild A Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood J. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017; 19:1813-1823.

177. Lim SY, Lee J, Welsh S, Ahn SB, Breen E, Khan A, Carlino M, Menzies A, Kefford R, Scolyer RA, Long GV, Rizos H. Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomark Res. 2017 Nov 10;5:32. doi: 10.1186/s40364-017-0112-9. eCollection 2017, PMID 29152306

178. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AN, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Min Kim T, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA., Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III or IV melanoma. N Engl J Med 2017. 377(19):1824-1835.


20

179. Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey L, Lao C, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino M, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi S, Larkin J. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2017; 377:1345-1356.

180. Glodde N, Bald T, Boorn-Konijnenberg D, Nakamura K, O`Donnell J, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, Van der Sluis T, Ruotsalainen J, Gaffal E, Landsberg J, Ludwig K, Wilhelm C, Riek-Burchardt M, Müller A, Gebhardt C, Scoyler R, Long GV, Janzen V, Teng M, Kastenmüller W, Mazzone M, Smyth M, Tüting T, Hölzel M. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity 2017; 47:789-802.

181. Sidhu P, Menzies AM, Carlino MS, Long GV, Kapoor R. Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy. J Med Imaging Radiat Oncol 2017. 61(6):759-766.

182. Gershenwald J, Scolyer RA, Hess K, Sondak V, Long GV, Ross M, Lazar A, Faries M, Kirkwood J,McArthur G,Haydu L, Eggermont A, Flaherty K, Balch C, Thompson J, and members of the AJCC Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA 2017. 67(6):472-492.

183. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka R, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood J, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman M, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell 2018; 174: 1031-1032.

184. Aivazian K, Long GV, Sinclair E, Kench JG, McKenzie CA. Histopathology of Pembrolizumab-Induced Hepatitis: a case report. Pathology 2017. 49(7): 789-792 [Epub ahead of print].

185. Rawson R, Robbins E, Kapoor R, Scoyler RA, Long GV. Recurrent bowel obstruction: unusual presentation of Pembrolizumab-induced pancreatitis in annular pancreas. Eur J Cancer 2017; 82:167-170.

186. Silvam IP, Long GV. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. Curr Opin Oncol. 2017 Nov;29(6):484-492. doi: 10.1097/CCO.0000000000000405.

187. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of novel therapies – Update 2017. Eur J Cancer 2017; 83:247-257.

188. Somasundaram R, Wagner SN, Zhang G, Perego M, Wagner C, Hristova D, Garg K, Hards R, Wei Z, Wu L, Frederick DT, Flaherty K, Scolyer RA, Long GV, Maurer M, Fukunaga-Kalabis M, Krepler C, Damle M, Ellingsworth C, Grinman L, Dunagin M, Raj A, Scholler N,Gross L, Beqiri M, Liu Q, Bennett K, Griss J, Schaider H, Czerniecki BJ,Schuchter L, Herlyn D, Herlyn M. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun 2017; 8:607.

189. Reinhardt J, Landsberg J, Schmid-Burgk JL, Bibiloni Ramis B, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long GV, Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M. MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. Cancer Res 2017; 77:4697-4709.

190. Mar VJ, Scolyer RA, Long GV. Computer-assisted diagnosis for skin cancer: have we been outsmarted? Lancet 2017; 389:1962-1964.

191. Kakavand H, Rawson R, Pupo G, Yang J, Menzies A, Carlino M, Kefford R, Howle J, Saw R, Thompson J, Wilmott J, Long GV, Scolyer R, Rizos H. PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clin Can Res 2017; 23:6054-6061.


21

192. Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol 2017. 30(12): 1666-1676.

193. Schadendorf D, Larkin J, Wolchok J, Hodi S, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey L, Lao C, Wagstaff J, Callahan M,. Postow M, Smylie M, Ferrucci P, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, Long GV. Health-related quality of life results from the phase III CheckMate 067 Study. Eur J Cancer 2017; 82: 80-91.

194. Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen J, Lebbé C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies M, Zhang Y, Kaper M, Mookerjee B, Legos J, Flaherty K, Robert C. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer 2017; 82: 45-55.

195. Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas D, Ahern E, Huntington N, Schadendorf D, Long GV, Boyle G, Hölzel M, Scolyer RA, Smyth MJ. Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. Cancer Res 2017; 77:4684-4696.

196. Long GV, Atkinson V, Cebon J, Jameson M, Fitzharris B, McNeil C, Hill A, Ribas A, Atkins M, Thompson J, Hwu W-J, Hodi S, Menzies A, Guminski A, Kefford R, Kong B, Tamjid B, Srivastava A, Lomax A, Islam Shu X, Ebbinghaus S, Ibrahim N, Carlino M. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma: the open-label, phase 1b KEYNOTE-029 study. Lancet Onc 2017; 18:1202-1210.

197. Vilain R, Menzies A, Wilmott J, Kakavand H, Madore J, Guminski A, Liniker E, Kong B, Cooper A, Howle J, Saw R, Jakrot V, Lo S, Thompson J, Carlino M, Kefford R, Long GV (shared senior author), Scolyer R. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin Cancer Res 2017; 23:5024-33.

198. Schachter J, Ribas A, Long GV, Arance A, Grob J-J, Mortier L, Daud A, Carlino M, Catriona McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella T, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017; 390:1853-1862.

199. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2017; 28:1631-1639.

200. Davies M, Saiag P, Robert C, Grob J-J, Flaherty K, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos S, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, MD, Zhang Y, Huang Y, Mookerjee B, Long GV. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 2017; 18(7):863-873.

201. Willmott J, Rizos H, Scolyer RA, Long GV. The "tricky business" of identifying mechanisms of resistance to anti-PD-1. Clin Cancer Res 2017; 23:2921-2923.

202. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch A-M, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, de Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm S-J, Pritchard A, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, Lopez-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ. Whole-genome landscapes of major melanoma subtypes. Nature 2017; 545:175-180.


22

203. Long GV, Weber JS, Larkin J, Atkinson V, Grob J-J, Schadendorf D, Dummer R, Robert C, Marquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain J-F, Hodi FS, Wolchok JD. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression Analysis of 2 Phase 3 Clinical Trials. JAMA Onc 2017; 3:1511-1519.

204. Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozon V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18:435-445.

205. Hendrix MJ, Kandela I, Mazar AP, Seftor EA, Seftor RE, Margaryan NV, Strizzi L, Murphy GF, Long GV, Scolyer RA. Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. Lab Invest. 2017 Feb;97(2):176-186. doi: 10.1038/labinvest.2016.107. Epub 2016 Oct 24 PMID 27775961

206. Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol 2017; 28:1130-1136.

207. Pupo G, Boyd SC, Fung C, Carlino MS, Menzies, AM, Pedersen, B, Johannson P, Hayward NK, Kefford RF, Scolyer RA, Long GV, Rizos H. Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. Biomark Res 2017; 5:17.

208. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463-482.

209. Menzies AM, Long GV. Optimum dosing of ipilimumab in melanoma: too little, too late? Lancet Oncol 2017; 18:558-559.

210. Eskiocak B, McMillan E, Mendiratta S, Kollipara R, Zhang H, Humphries C, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales T, Eskiocak U, Smith MP, Sudderth J, Komurov K, DeBerardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, Long GV, Kittler R, White M. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov 2017; 7(8); 832–51.

211. Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV (shared senior author), Hellmann MD. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017 Mar;35(7):709-717. doi: 10.1200/JCO.2016.68.2005. Epub 2016 Sep 30 PMID: 27646942

212. ODonnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer treatment reviews 2017; 52:71-81.

213. Parakh S, Park JJ, Mendis S, Rai R, Xu W, Lo S, Drummond M, Rowe C, Wong A, McArthur G, Haydon A, Andrews MC, Cebon J, Guminski A, Kefford RF, Long GV, Menzies AM, Klein O, Carlino MS. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer, 2017; 116:1558-1563.

214. Choong ES, Lo S, Drummond M, Fogarty GB, Menzies AM, Guminski A, Shivalingam B, Clarke K, Long GV, Hong AM. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. Eur J Cancer 2017; 75:169-178.

215. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoustari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017; 28:368-376.

216. Atkinson V, Long GV, Menzies AM, McArthur G, Carlino MS, Millward M, Roberts-Thomson R, Brady B, Kefford R, Haydon A, Cebon J. Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia Pac J Clin Oncol 2016; 7:5-12


23

217. Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 2016; 17:1743-1754.

218. Carlino MS, Vanella V, Girgis C, Giannarelli D, Guminski A, Festino L, Kefford RF, Menzies AM, Long GV, Ascierto PA. Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. Br J Cancer 2016; 115:1280-1284.

219. Arnheiter H, Long G, Aplin A, Harris J, Kelsh R. Triple jeopardy for people with albinism. Pigment Cell Melanoma Res 2016; 29(5):48.

220. Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, Geukes Foppen MH, Scolyer R, Song JY, Verbrugge I, Hoeller C, Dummer R, Haanen JB, Long GV, Blank CU. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. Oncoimmunology 2016. [Epub ahead of print]5(12): e1238557.

221. Menzies AM, Long GV. Recent Developments in Melanoma Therapy. JAMA Oncol 2016; 2:1259-1260.

222. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, Jiang J, Caroline Robert C. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients with Advanced Melanoma. J Clin Oncol 2017; 35:785-792.

223. Long G, Hoadley A, Sandanayake N. Atrophic Exocrine Pancreatic Insufficiency Associated with Anti-PD1 Therapy. Ann Oncol 2017; 28(2):434-435.

224. Thompson, JF, Shivalingam, B, Hong AM, Lyle, M, Long, GV, Chapter 5 – Brain Metastases from Melanoma, Brain Metastases from Primary Tumours, Volume 3, 2016 October 21

225. Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, Carlino MS, Hong A, Long GV. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology 2016. 5(9): e1214788.

226. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res 2016; 29:404-416.

227. Long GV, Atkinson V, Ascierto PA, Robert C, Hassel JC, Rutkowski P, Savage KJ, Taylor F, Coon C, Gilloteau I, Dastani HB, Waxman IM, Abernethy AP. Effect of nivolumab on health-related quality of life in patients with treatment-naive advanced melanoma: results from the phase III CheckMate 066 study. Ann Oncol 2016; 27:1940-1946.

228. Kong BY, Menzies AM, Saunders CA, Liniker E, Ramanujam S, Guminski A, Kefford RF, Long GV, Carlino MS. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell Melanoma Res 2016; 29:572-577.

229. Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E, Saw RP, Yu B, Cooper WA, Long GV, OToole SA, Scolyer RA. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology 2016; 69:680-686.

230. Carlino MS, Long GV. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma? Clin Cancer Res 2016; 22:3992-3998.

231. Ascierto PA, Long GV. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. Lancet Oncol 2016; 17:1037-1039

232. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, OConnell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA,


24

Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 2016; 537:254.

233. De Paoli-Iseppi R, Johansson PA, Menzies AM, Dias KR, Pupo GM, Kakavand H, Wilmott JS, Mann GJ, Hayward NK, Dinger ME, Long GV, Scolyer RA. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology 2016; 48:261-266.

234. Welsh SJ, Rizos H, Scolyer RA, Long GV. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? Eur J Cancer 2016; 62:76-85.

235. Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O. Reply to Comment on Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer 2017; 116:e15.

236. Madore J, Strbenac D, Vilain R, Menzies AM, Yang JY, Thompson JF, Long GV, Mann GJ, Scolyer RA, Wilmott JS. PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clin Cancer Res 2016; 22:3915-3923.

237. Lyle M, Haydu LE, Menzies AM, Thompson JF, Saw RP, Spillane AJ, Kefford RF, Mann GJ, Cooper WA, Yu B, Scolyer RA, OToole SA, Long GV. The molecular profile of metastatic melanoma in Australia. Pathology 2016; 48:188-193.

238. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. Eur J Cancer 2016; 53:125-134.

239. Pulvirenti T, Hong A, Clements A, Forstner D, Suchowersky A, Guminski A, Mcneil C, Hersey P, Fogarty G, Kefford R, Long GV, Wang W. Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. J Clin Oncol 2016 Jan 20;34(3):e17-20. doi: 10.1200/JCO.2013.49.0565. Epub 2014 May 2.

240. Kakavand H, Wilmott JS, Long GV, Scolyer RA. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology 2016; 48:194-202.

241. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol 2016; 2:234-240.

242. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol 2016; 34:871-878.

243. Menzies AM, Atkinson VG, Brown MP, Carlino MS, Cebon J, Guminski A, Kefford RF, Long GV, McArthur G, McNeil CM, Millward M, Sandhu S. Sentinel node biopsy for melanoma: The medical oncology perspective. Aust Fam Physician 2015; 44(12):875-876.

244. Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, Haney P, OHagan A, Carver J, Goodman V, Legos J, Martin AM. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clin Cancer Res 2016; 22:567-574.

245. Liang R, Meiser B, Smith S, Kasparian N, Lewis C, Chin M, Long GV, Ward R, Menzies AM, Guminski A, Harris-Wai J, Kaur R. Oncology patients attitudes toward, and experiences with, somatic mutation tumour testing. Asia Pac J Clin Oncol 2015; 11:144.


25

246. Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, Opatt McDowell D, Mookerjee B, Schadendorf D, Robert C. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol 2015; Oct: 16(13);1389-1398.

247. Grob JJ, Long GV, Schadendorf D, Flaherty K. Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. Lancet Oncol 2015; Oct: 16(13);e522–e526.

248. Carlino MS, Long GV, Kefford RF, Rizos H. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. Crit Rev Oncol Hematol 2015; Dec: 96(3):385-398.

249. Gray, E. S., Rizos, H., Reid, A. L., Boyd, S. C., Pereira, M. R., Lo, J., Tembe, V., Freeman, J., Lee, J. H., Scolyer, R. A., Siew, K., Lomma, C., Cooper, A., Khattak, M. A., Meniawy, T. M., Long, G. V., Carlino, M. S., Millward, M., & Ziman, M. (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma, Oncotarget. 2015 Dec 8;6(39):42008-18. doi: 10.18632/oncotarget.5788, PMID: 26524482

250. Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, Hersey P, Long GV, Scolyer RA. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Mod Pathol 2015; Dec: 28:1535-1544.

251. Arnheiter H, Long GV, Aplin A, Harris J, Kelsh, Welcome to the New Year!, (Editorial) Pigment Cell & Melanoma Research, 2015 Dec 15, doi.org/10.1111/pcmr.12446

252. Johnson DB, Menzies AM, Zimmer L, Eroglud Z, Yea F, Zhaoa S, Rizos H, Sucker A, Scolyer RA, Gutzmerj R, Gogas H, Kefford RF, Thompson JT, Becker JC, Berking C, Egbertsn F, Loquai C, Goldinger S, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behavior, and phenotypic associations of resistance mechanisms. Eur J Cancer 2015; Dec: 51(18):2792-2799.

253. Carlino MS, Long GV. Is chemotherapy still an option in the treatment of melanoma? Ann Oncol 2015; Nov: 26(11):2203-4.

254. Ramsdale R, Jorissen RN, Li FZ, Al-Obaidi S, Ward T, Sheppard KE, Bukczynska PE, Young RJ, Boyle SE, Shackleton M, Bollag G, Long GV, Tulchinsky E, Rizos H, Pearson RB, McArthur GA, Dhillon AS, Ferrao PT. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Sci Signal 2015; Aug: 18:8(390):ra82.

255. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; Aug; 1:386(9992):444-51.

256. Theodosakis N, Meeth K, Micevic G, Scolyer RA, Long GV, Marzuka A, Stern D, Bosenberg M. BRAF inhibition decreases cellular glucose uptake in melanoma in association with reduction in cell volume. Mol Cancer Ther 2015; Jul: 14(7):1680-92.

257. Amaravadi RK, Hamilton KE, Ma X, Piao S, Del Portillo A, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJD, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR. Multiple gastrointestinal polyps in patients treated with BRAF inhibitors. Clin Cancer Res 2015; Dec: 21(23):5215-21

258. Menzies AM, Wilmott JS, Drummond M, Lo S, Lyle M, Chan MMK, Thompson JF, Guminski A, Carlino MS, Scolyer RA, Kefford RF, Long GV. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer 2015; Nov: 121(21):3826-35.


26

259. Ramanujam S, Schadendorf D, Long GV. Systemic therapies for melanoma brain metastases: which drug for whom and when? Chin Clin Oncol 2015; Jun: 4(2):25. doi: 10.3978/j.issn.2304-3865.2015.06.06.

260. Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, Arachchi H, Arora A, Auman JT, Ayala B, Baboud J, Balasundaram M, Balu S, Barnabas N, Bartlett J, Bartlett P, Bastian BC, Baylin SB, Behera M, Belyaev D, Benz C, Bernard B, Beroukhim R, Bir N, Black AD, Bodenheimer T, Boice L, Boland G, Bono R, Bootwalla MS, Bosenberg M, Bowen J, Bowlby R, Bristow CA, Brockway-Lunardi L, Brooks D, Brzezinski J, Bshara W, Buda E, Burns WR, Butterfield YSN, Button M, Calderone T, Cappellini GA, Carter C, Carter SL, Cherney L, Cherniack AD, Chevalier A, Chin L, Cho J, Cho RJ, Choi YL, Chu A, Chudamani S, Cibulskis K, Ciriello G, Clarke A, Coons S, Cope L, Crain D, Curley E, Danilova L, D'Atri S, Davidsen T, Davies MA, Delman KA, Demchok JA, Deng QA, Deribe YL, Dhalla N, Dhir R, DiCara D, Dinikin M, Dubina M, Ebrom JS, Egea S, Eley G, Engel J, Eschbacher JM, Fedosenko KV, Felau I, Fennell T, Ferguson ML, Fisher S, Flaherty KT, Frazer S, Frick J, Fulidou V, Gabriel SB, Gao J, Gardner J, Garraway LA, Gastier-Foster JM, Gaudioso C, Gehlenborg N, Genovese G, Gerken M, Gershenwald JE, Getz G, Gomez-Fernandez C, Gribbin T, Grimsby J, Gross B, Guin R, Gutschner T, Hadjipanayis A, Halaban R, Hanf B, Haussler D, Haydu LE, Hayes DN, Hayward NK, Heiman DI, Herbert L, Herman JG, Hersey P, Hoadley KA, Hodis E, Holt RA, Hoon DSB, Hoppough S, Hoyle AP, Huang FW, Huang M, Huang S, Hutter CM, Ibbs M, Iype L, Jacobsen A, Jakrot A, Janning A, Jeck WR, Jefferys SR, Jensen MA, Jones CD, Jones SJM, Ju Z, Kakavand H, Kang H, Kefford RF, Khuri FR, Kim J, Kirkwood JM, Klode J, Korkut A, Korski K, Krauthammer M, Kucherlapati R, Kwong LN, Kycler W, Ladanyi M, Lai PH, Laird PW, Lander E, Lawrence MS, Lazar AJ, Łaźniak R, Lee D, Lee JE, Lee J, Lee K, Lee S, Lee S, Leporowska E, Leraas KM, Li HI, Lichtenberg TM, Lichtenstein L, Lin P, Ling S, Liu J, Liu O, Liu W, Long GV, Lu Y, Ma S, Ma Y, Mackiewicz A, Mahadeshwar HS, Malke J, Mallery D, Manikhas GM, Mann GJ, Marra MA, Matejka B, Mayo M, Mehrabi S, Meng S, Meyerson M, Mieczkowski PA, Miller JP, Miller ML, Mills GB, Moiseenko F, Moore RA, Morris S, Morrison C, Morton D, Moschos S, Mose LE, Muller FL, Mungall AJ, Murawa D, Murawa P, Murray PA, Nezi L, Ng S, Nicholson D, Noble MS, Osunkoya A, Owonikoko TK, Ozenberger BA, Pagani E, Paklina OV, Pantazi A, Parfenov M, Parfitt J, Park PJ, Park WY, Parker JS, Passarelli F, Penny R, Perou CM, Pihl TD, Potapova O, Prieto VG, Protopopov A, Quinn MJ, Radenbaugh A, Rai K, Ramalingam SS, Raman AT, Ramirez NC, Ramirez R, Rao U, Rathmell WK, Ren X, Reynolds SM, Roach J, Robertson AG, Ross MI, Roszik J, Russo G, Saksena G, Saller C, Samuels Y, Sander C, Sander C, Sandusky G, Santoso N, Saul M, Saw RPM, Schadendorf D, Schein JE, Schultz N, Schumacher SE, Schwallier C, Scolyer RA, Seidman J, Sekhar PC, Sekhon HS, Senbabaoglu Y, Seth S, Shannon KF, Sharpe S, Sharpless NE, Mills Shaw KR, Shelton C, Shelton T, Shen R, Sheth M, Shi Y, Shiau YJ, Shmulevich I, Sica GL, Simons JV, Sinha R, Sipahimalani P, Sofia HJ, Soloway MG, Song X, Sougnez C, Spillane AJ, Spychała A, Stretch JR, Stuart J, Suchorska WM, Sucker A, Sumer So, Sun Y, Synott M, Tabak B, Tabler TR, Tam A, Tan D, Tang J, Tarnuzzer R, Tarvin K, Tatka H, Taylor BS, Teresiak M, Thiessen N, Thompson JF, Thorne L, Thorsson V, Trent JM, Triche Jr TJ, Tsai KY, Tsou P, Van Den Berg DJ, Van Allen Em, Veluvolu U, Verhaak RG, Voet D, Voronina O, Walter V, Walton JS, Wan Y, Wang Y, Wang Z, Waring S, Watson IR, Weinhold N, Weinstein JN, Weisenberger DJ, White P, Wilkerson MD, Wilmott JS, Wise L, Wiznerowicz M, Woodman SE, Wu CJ, Wu CC, Wu J, Wu Y, Xi R, Xu AW, Yang D, Yang L, Yang L, Zack TI, Zenklusen JC, Zhang H, Zhang J, Zhang W, Zhao X, Zhu J, Zhu K, Zimmer L, Zmuda E, Zou L Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. 2015 Jun 18;161(7):1681-96. doi: 10.1016/j.cell.2015.05.044 PMID: 26091043

261. Menzies AM, Yeh I, Botton T, Bastian BC, Scolyer RA, Long GV. Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. Pigment Cell Melanoma Res 2015; Sep: 28(5):607-10.

262. Stark M, Klein K, Weide B, Haydu L, Pflugfelder A, Tang YH, Palmer J, Whiteman D, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour A, Soyer HP, Garbe C, Herington A, Pollock P, Hayward N. The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: a microRNA expression analysis. EBioMedicine 2015; May: 12;2(7):671-80.


27

263. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Cowey L, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossman K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; Jul: 2;373(1):23-34.

264. Lam T, Chan MMK, Sweeting AN, De Sousa SMC, Clements A, Carlino MS, Long GV, Tonks K, Chua E, Kefford RF, Chipps DR. Ipilimumab-induced hypophysitis in melanoma patients: An Australian case series. Intern Med J 2015; Oct: 45(10):1066-73.

265. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, Long GV. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer 2015; May: 51(7):833-40.

266. Robert C, Schachter J, Long GV, Arance A, Grob J-J, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer-R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; Jun: 25;372(26):2521-32

267. Anforth R, Menzies AM, Byth K, Carlos G, Chou S, Sharma R, Scolyer RA, Kefford RF, Long GV, Fernandez-Penas P. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. J Am Acad Dermatol 2015; May; 72(5):809-15.e1.

268. Wilmott JS, Hersey P, Long GV, Scolyer RA. Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? Melanoma Manag 2015; 2(1):15–19.

269. Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, Scolyer RA. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clin Cancer Res 2015; 21(14):3140-48.

270. Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol 2015; Jan: 16(1):15-17.

271. Phan TG, Long GV, Scolyer RA. Multiple checkpoints on the long road towards cancer immunotherapy. Immunol Cell Biol 2015; Apr: 93(4):323-5.

272. Wilmott JS, Colebatch A, Kakavand H, Shang P, Carlino MS, Thompson JF, Long GV, Scolyer RA, Hersey P. Expression of the Class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Mod Pathol 2015; Jul: 28(7):884-94.

273. Madore J, Vilain R, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, Long GV, Hersey P, Scolyer RA. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2015; May: 28(3):245-53.

274. Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann Oncol 2015; Feb: 26(2):415-21.

275. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin A-M, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med 2015; Jan: 1;372(1):30-9.

276. Long GV, Fung C, Menzies AM, Pupo G, Carlino M, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, Howle J, Hayward N, Johansson P, Scolyer RA, Kefford RF, Rizos H.


28

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF mutant metastatic melanoma. Nat Commun 2014; Dec: 2:5:5694

277. Carlino MS, Fung C, Shahheydari H, Todd JR, Nagrial, AM, Scolyer RA, Kefford RF, Long GV, Rizos, H. Pre-existing MEK1 P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Clin Cancer Res 2015; Jan: 1;21(1):98-105

278. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassell JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA. Nivolumab in Previously Untreated Melanoma without BRAF mutation. N Engl J Med 2015; Jan: 22;372(4):320-30

279. Long GV. From dismal prognosis to rising star: melanoma leading the way with new generation cancer therapies. Med J Aust 2015; Feb: 16:202(3):115-6.

280. Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients with BRAFV600-Mutant Melanoma Experiencing Progression with Single-Agent BRAF Inhibitor. J Clin Oncol 2014; Nov: 20:32(33):3697-704.

281. Gopal VNV, Rizos H, Chen G, Deng W, Frederick DT, Cooper ZA, Scolyer RA, Pupo G, Komurov K, Sehgal V, Zhang J, Patel L, Pereira CG, Broom BM, Mills GB, Ram P, Smith PD, Wargo JA, Long GV, Davies MA. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and Oxidative Phosphorylation in melanoma. Cancer Res 2014; Dec: 1:74(23):7037-47.

282. Sutton SK, Koach J, Tan O, Liu B, Carter DR, Wilmott JS, Yosufi B, Haydu LE, Mann GJ, Thompson JF, Long GV, Liu T, McArthur G, Zhang XD, Scolyer RA, Cheung BB, Marshall GM. TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget 2014; Oct: 30:5(20):10127-39.

283. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi, V.; Kovalenko, N.; Mohr, P.; Probachai, V.; Schadendorf, D.; Nathan, P.; Robert, C.; Ribas, A.; DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin A-M, Le N, Patel K, Flaherty K. Combined BRAF and MEK Inhibition Versus BRAF Inhibition Alone in Melanoma. N Engl J Med 2014; Nov: 13:371(20):1877-88.

284. Wang, J., Huang, S. K., Marzese, D. M., Hsu, S. C., Kawas, N. P., Chong, K. K., Long, G. V., Menzies, A. M., Scolyer, R. A., Izraely, S., Sagi-Assif, O., Witz, I. P., & Hoon, D. S. B. (2015). Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol . 2015 Feb;135(2):532-541. doi: 10.1038/jid.2014.418. Epub 2014 Sep 22 PMID: 25243790

285. De Sousa, S, Long GV, Tonks K. Ipilimumab-induced hypophysitis: early Australian experience. Med J Aust 2014; Aug: 18:201(4):198-9.

286. Long GV, Falchook GS, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin M, ODay SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436). Clin Cancer Res 2014; Sept: 1:20(17):4449-58.

287. Lee CI, Menzies AM, Haydu LE, Azer M, Clements A, Kefford RF, Long GV. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Mel Res 2014; Oct: 24:(5):468-74.

288. Zimmer L, Haydu LE, Menzies AM, Scolyer RA, Kefford RF, Thompson JF, Schadendorf D, Long GV. Reply to M. Perier-Muzet et al. J Clin Oncol 2014; Oct: 1:32(28):3203-4.


29

289. Bowyer SE, Rao A, Lyle M, Sandhu S, Long GV, McArthur G, Raleigh J, Hicks R, Millward M Activity of Trametinib in K601E and L597Q BRAF Mutation-Positive Metastatic Melanoma. Mel Res 2014; Oct: 24(5):504-8.

290. Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, NG CC, Cooper W, Thompson JF, Kefford RF, OToole SO, Scolyer RA, Long GV. Correlation of BRAF and NRAS mutation status with outcome, organ involvement and response to chemotherapy in metastatic melanoma. Br J Cancer 2014; Jul: 15:111(2):292-9.

291. Chan, M. M., Haydu, L. E., Menzies, A. M., Azer, M. W., Klein, O., Lyle, M., Clements, A., Guminski, A., Kefford, R. F., & Long, G. V. (2014). The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition, Cancer. 2014 Oct 15;120(20):3142-53. doi: 10.1002/cncr.28851. Epub 2014 Jul 1, PMID: 24985732

292. Chien A, Haydu LE, Biechele TL, Kulikauskas RM, Rizos H, Kefford RF, Scolyer RA, Moon RT, Long GV. Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/beta-catenin signaling. PlosOne 2014; Apr: 14:9(4):e94748.

293. Brown MP, Long GV. The Use of Vemurafenib in Australian Patients with Unresectable or Metastatic Melanoma Containing the V600 BRAF Gene Mutation. Asia-Pac J Clin Oncol 2014; Apr: (10):suppl S3:1-15.

294. Menzies AM, Long GV. Systemic treatment for BRAF-mutant melanoma: Where do we go next? Invited Review. Lancet Oncol 2014; Aug: 15(9):e371-81.

295. Menzies AM, Long GV. Dabrafenib and Trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Invited review. Clin Cancer Res 2014; Apr: 15:20(8):2035-43.

296. Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AMM, Hauschild A, Kefford R, Kirkwood JM, Long GV, Lorigan P, Mackensen A, McArthur G, ODay S, Patel PM, Robert C, Schadendorf D. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol. 2014; Mar: 15(3):297-304.

297. Wilmott JS, Haydu LE, Menzies AM, Lum T, Hyman J, Thompson JF, Hersey P, Kefford RF, Scolyer RA, Long GV. Dynamics of chemokine, cytokine, and growth factor seum levels in BRAF- mutant melanoma patients during BRAF inhibitor treatment. Journal Immun 2014; Mar: 1:192(5):2505-2513.

298. Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, Scolyer RA, Long GV. BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact. Clin Cancer Res 2014; Apr: 1:20(7):1965-77.

299. Carlino M, Todd J, Gowrishankar K, Mijatov B, Pupo G, Snoyman S, Hersey P, Long GV, Kefford RF, Rizos H. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol 2014; May: 8(3):544-54.

300. Anastas JN, Tamir T, Kulikauskas RM, Rizos H, Long GV, Euw EM, Chen H-W, Haydu L, Yang P-T, Toroni RA, Lucero OM, Chien AJ, Moon RT. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors and promotes cell growth and survival through activation of AKT signaling. J Clin Inv 2014; Jul: 1:124(7):2877-90.

301. Parmenter T, Kleinschmidt M, Kinross K, Bond S, Li J, Kaadige M, Sheppard K, Hugo W, Pupo G, Pearson R, McGee S, Long GV, Scolyer R, Rizos H, Lo R, Cullinane C, Ayer D, Ribas A, Johnstone R, Hicks R, McArthur G. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov 2014; Apr: 4(4):423-33.

302. Shi H, Hong A, Kong X, Koya R, Song C, Moriceau G, Hugo W, Yu C, Ng C, Chodon T, Scolyer R, Kefford R, Ribas A, Long GV, Lo R, A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov 2014; 4(1):69-79.

303. Shi H, Willy H, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson D, Dahlman KB, Kelley M, Kefford RF, Chmielowski B, Glaspy J, Sosman JA, Long GV, Ribas A, Lo R, Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014; 4(1):80-93.


30

304. Lyle M, Long GV. The Role of Systemic Therapies in the Management of Melanoma Brain Metastases. Current Opin Onc 2014; 26(2):222-9.

305. Menzies AM, Haydu LE, Carlino M, Azer MF, Carr PJA, Kefford RF, Long GV. Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PlosOne 2014; 9(1):e85004.

306. Carlino MS, Kwan V, Miller DK, Saunders CAB, Yip D, Nagrial AM, Tomlinson J, Grimmond SM, Scolyer RA, Kefford RF, Biankin AV, Long GV. New RAS-mutant Pancreatic Adenocarcinoma with Combined BRAF and MEK inhibition for Metastatic Melanoma. J Clin Oncol 2014; Apr: 10:33(11).

307. Kakavand H, Crainic O, OToole S, Kefford RF, Thompson JF, Wilmott JS, Long GV, Scolyer RA. Concordant BRAFV600E mutation status in primary melanomas and associated nevi: implications for mutation testing of primary melanomas. Pathol 2014; 46(3):193-198.

308. Lezcano C, Lee C-W, Larson AR, Menzies AM, Kefford RF, Thompson JF, Mihm MC, Ogino S, Long GV, Scolyer RA, Murphy GF Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Mod Pathol 2014; Sep: 27(9):1193-202.

309. Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi SF, Kefford RF, Menzies AM, Atkins MB, Cho DC, Sullivan RJ, Long GV (shared senior author). Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after targeted therapy. Cancer 2014; Jun: 1:120(11):1695-1701

310. Azer MWF, Menzies AM, Haydu LE, Kefford RF, Long GV. Patterns of Response and Progression in Patients with BRAF-mutant Melanoma Metastatic to the Brain treated with Dabrafenib. Cancer 2014; 120:530-6.

311. Zimmer L, Haydu LE, Menzies AM, Scolyer RA, Richard F. Kefford RF, John F. Thompson JF, Schadendorf D, Long GV. Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. J Clin Oncol 2014; Mar: 10;32(8):816-23.

312. Menzies AM, Wilmott JS, Long GV, Scolyer RA. Intra-patient heterogeneity of BRAF mutation status: fact or fiction? Br J Cancer 2014; Mar: 38(3):377-82.

313. Menzies AM, Lum T, Wilmott JS, Hyman J, Kefford RF, Thompson JF, OToole S, Long GV, Scolyer RA. Intrapatient homogeneity of BRAFV600E expression in melanoma. Am J Surg Path 2014; Mar: 38(3):377-82.

314. Hu W, Jin L, Jiang CC, Long GV, Scolyer RA, Wu Q, Zhang XD, Mei Y, Wu M. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Cell Death Dis. 2013; 4:e914.

315. Lyle M, Long GV. Diagnosis and Treatment of KIT-Mutant Metastatic Melanoma. Invited review J Clin Oncol 2013; 31:3176-81.

316. Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, Long GV, Fernandez-Peñas P. Acneiform Eruptions: A Common Cutaneous Toxicity of the MEK Inhibitor Trametinib. Australas J Derm 2014; Nov: 55(4):250-4 .

317. Menzies AM, Long GV. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. Eur J Cancer 2013; 49(15):3229-41.

318. Anforth R, Blumetti TCMP, Clements A, Kefford R, Long GV, Fernandez-Peñas P. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Br J Dermatol. 2013; 169:1310-3.

319. Menzies AM, Kefford RF, Long GV. Paradoxical oncogenesis: are all BRAF inhibitors equal? Pigment Cell Melanoma Res 2013; 26(5):611-5.

320. Nathanson KL, Martin A-M, Wubbenhorst B, Greshock J, Letrero R, DAndrea K, ODay S, Infante JR, Falchook GS, Arkenau H-T, Millward M, Brown MP, Pavlick A, Davies MA, Ma B, Gagnon R, Curtis M, Lebowitz PF, Kefford RF, Long GV. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor Dabrafenib (GSK2118436). Clinical Cancer Res 2013; 19(17):4868-4878.


31

321. Menzies AM, Long GV. New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Invited review Ther Adv Med Oncol 2013; 5:278-85.

322. Ascierto PA, Minor D, Ribas A, Lebbe C, OHagan A, Arya N, Guckert M, Schadendorf D, Kefford R, Grob J-J, Hamid O, Amaravadi R, Simeone E, Wilhelm T, Kim KB, Long GV, Martin A-M, Mazumdar J, V Goodman V, Trefzer U. A Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013; 31:3205-3211.

323. Long, G. V., Wilmott, J. S., Haydu, L. E., Tembe, V., Sharma, R., Rizos, H., Thompson, J. F., Howle, J., Scolyer, R. A., & Kefford, R. F. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigment Cell Melanoma Res. 2013 Jul;26(4):499-508. doi: 10.1111/pcmr.12098. Epub 2013 May 3, PMID 23557327

324. Carlino, M. S., Gowrishankar, K., Saunders, C. A., Pupo, G. M., Snoyman, S., Zhang, X. D., Saw, R., Becker, T. M., Kefford, R. F., Long, G. V., & Rizos, H. (2013). Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma, Mol Cancer Ther. 2013 Jul;12(7):1332-42. doi: 10.1158/1535-7163.MCT-13-0011. Epub 2013 May 3, PMID: 23645591

325. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Peter Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi R K, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients with Metastatic Melanoma. J Clin Oncol 2013; 31:1767-74.

326. Long GV, Margolin KA. Multidisciplinary Approach to Brain Metastasis from Melanoma; Systemic Targeted Therapies for CNS Metastases. Invited review American Society of Clinical Oncology Educational Book, 2013; 393-8.

327. Wilmott, J. S., Menzies, A. M., Haydu, L. E., Capper, D., Preusser, M., Zhang, Y. E., Thompson, J. F., Kefford, R. F., von Deimling, A., Scolyer, R. A., & Long, G. V. (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma, Br J Cancer. 2013 Mar 5;108(4):924-31. doi: 10.1038/bjc.2013.29. Epub 2013 Feb 12 PMID 23403819.

328. Lo RS, A. Ribas A, Long GV, Ballotti R, Berger M, Hugo W, Gibney GT, Bosenberg M, Bernstein E, Villanueva J, Smalley KSM. Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California. Pigment Cell Melanoma Res 2013; 26:E1-7.

329. Anforth RM, Fernandez-Penas P, Long GV. Cutaneous Toxicities of RAF Inhibitors. Invited review Lancet Onc 2013; 14:e11-8.

330. Kim, K. B., Kefford, R., Pavlick, A. C., Infante, J. R., Ribas, A., Sosman, J. A., Fecher, L. A., Millward, M., McArthur, G. A., Hwu, P., Gonzalez, R., Ott, P. A., Long, G. V., Gardner, O. S., Ouellet, D., Xu, Y., DeMarini, D. J., Le, N. T., Patel, K., & Lewis, K. D. (2013). Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor, J Clin Oncol. 2013 Feb 1;31(4):482-9. doi: 10.1200/JCO.2012.43.5966. Epub 2012 Dec 1 PMID: 23248257

331. Klein O, Clements A, Menzies A, Kefford R, Long GV. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer 2013; 49:1797-8.

332. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford R. Sosman JA, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi AP, Lewis KD, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber JS. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-703.

333. Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Invited review Drug Des Develop Ther 2012; 6:391-40.

334. Klein O, Ribas A, Chmielowski B, Walker G, Clements A, Long GV, Kefford K. Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. J Clin Oncol 2013; 31:e215-7.


32

335. Carlino, M. S., Saunders, C. A., Haydu, L. E., Menzies, A. M., Martin Curtis, C., Jr., Lebowitz, P. F., Kefford, R. F., & Long, G. V. (2013). (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma, Eur J Cancer. 2013 Jan;49(2):395-402. doi: 10.1016/j.ejca.2012.08.018. Epub 2012 Sep 1, PMID: 22981500

336. Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA, Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J of Surg Path 2013; 37:61-5.

337. Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., Mortier, L., Tawbi, H., Wilhelm, T., Zimmer, L., Switzky, J., Swann, S., Martin, A. M., Guckert, M., Goodman, V., Streit, M., Kirkwood, J. M., & Schadendorf, D. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial, Lancet Oncol. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub 2012 Oct 8, PMID 23051966

338. Anforth RM, Blumetti TCMP, Kefford RF, Sharma R, Scolyer RA, Kossard S, Long GV, Fernandez-Penas, P. Cutaneous Manifestations of GSK2118436, A Selective Inhibitor of Mutant BRAF in patients with Metastatic Melanoma. Br J Dermatol 2012; 167:1153-60.

339. Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, Lo RS, Kefford RF, Scolyer RA, Long GV. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mole Can Therap 2012; 12:2704-8.

340. Murali R, Brown PT, Kefford RF, Scolyer RA, Thompson JF, Atkins MB, Long GV. Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. Cancer 2012; 118:4519-29.

341. Menzies AM, Long GV. Clinicopathologic Features of V600E and V600K Melanoma—Response. Clin Cancer Res. 2012; 18(24):6793.

342. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV. Distinguishing Clinicopathologic Correlates of BRAF mutant V600E and V600K Metastatic Melanoma. Clin Can Res 2012; 18:3242-9.

343. Long GV, Falchook G (shared first authorship), Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, ODay SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet, 2012; 379:1893-90.

344. Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M. E., Busam, K., Carvajal, R. D., Egberts, F., Hauschild, A., Kashani-Sabet, M., Goldinger, S. M., Dummer, R., Long, G. V., McArthur, G., Scherag, A., Sucker, A., & Schadendorf, D. (2012). Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition, J Clin Oncol. 2012 Jul 1;30(19):2375-83. doi: 10.1200/JCO.2011.41.1660. Epub 2012 May 21, PMID: 22614973

345. Wilmott JS, Scolyer RA, Long GV, Hersey P. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Invited review OncoImmunology, 2012; 1:997-999.

346. Shi, H., Moriceau, G., Kong, X., Koya, R. C., Nazarian, R., Pupo, G. M., Bacchiocchi, A., Dahlman, K. B., Chmielowski, B., Sosman, J. A., Halaban, R., Kefford, R. F., Long, G. V., Ribas, A., & Lo, R. S. (2012). Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors, Cancer Discov. 2012 May;2(5):414-24. doi: 10.1158/2159-8290.CD-12-0022. Epub 2012 Apr 1, PMID 22588879

347. Carlino M S, Fogarty GB, Long GV. Treatment of melanoma brain metastases: A new paradigm. Invited review The Cancer J 2012; 18:208-12.


33

348. Murali R, Haydu LE, Quinn MJ, Saw RPM, Shannon K, Spillane AJ, Stretch JR, Thompson JF, Long GV, Scolyer RA. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. Ann Surg Oncol 2012; 19:1782-9.

349. Shi H, Moriceau G, Kong X, Lee M, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman J, Kefford R, Long GV, Nelson SF, Ribas A, Lo R. Melanoma exome sequencing identifies V600E BRAF amplification driving acquired resistance to vemurafenib. Nat Commun 2012; 3:724.

350. Long GV, Wilmott J (shared first authorship), Sharma RN, Howle JR, Thompson J, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce Marked T cell Infiltration into Human Melanoma. Clin Cancer Res, 2012, 18:1386-94.

351. Scolyer R, Long GV, Thompson JF. Evolving Concepts in Melanoma Classification and Their Relevance to Multidisciplinary Melanoma Patient Care. Invited review Mol Oncol 2011; 5:124-136.

352. Long GV, Menzies AM, Nagrial AM, Haydu L, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford, RF. Prognostic and clinico-pathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29:1239-46.

353. Arkenau H-T, Kefford R, Long GV. Targeting B-RAF for patients with melanoma. Invited review Br J Cancer 2011; 104:392-398.

354. Long GV. Book Review of The molecular biology of the cell Eds. Pelengaris and Khan, 2007. Cancer Forum 2007; 31:121.

355. Long GV, Tattersall MH. Lung encasement by metastatic osteoblastic sarcoma. Med J Aust 2007; 186:100.

356. Fernandez–Lopez S, Kim H-S, Choi E, Delgado M, Granja J, Khasanov K, Long GV, Weinberger D, Wilcoxen K, Ghadiri MR. Antibacterial Agents based on the Cyclic D,L--Peptide Architecture. Nature 2001; 412:452-55.

357. Long GV, Harding MM, Turner P. X-ray Structure of the Zinc Complex of the Central Metal Chelation site of the Antitumour Drug Streptonigrin. Polyhedron 2000; 19:1067-1071.

358. Harding MM, Long GV. Interaction of the Antitumour Antibiotic Streptonigrin with Metal Ions and DNA. Curr Med Chem 1997; 4:405-420.

359. Long GV, Harding MM, Fan J-Y, Denny WA. Interaction of the Antitumour Antibiotic Streptonigrin with DNA and Oligonucleotides. Anti-cancer Drug Des 1997; 12:453-472.

360. Long, G.V., Harding, M.M., A proton nuclear magnetic resonance study of the interaction of zinc(II) with the antitumour drug streptonigrin, Journal of Chemical Society, 1996

361. Long GV, Harding MM, Turner P, Hambley TW. Copper(II) Bipyridyl and Iminopyridyl Analogues of Streptonigrin. J Chem Soc, Dalton Trans 1995; 3905-3910.

362. Long GV, Harding MM, Xie MCL, Buys IE, Hambley TW. 3- Amino-6,6-bis(methoxycarbonyl)-2,2-bipyridine, a Model for the Central Chelation Unit of Streptonigrin. J Chem Soc, Dalton Trans 1995; 951-955.

363. Long GV, Boyd SE, Harding MM, Buys IE, Hambley TW. Synthesis, Properties and Complexation Studies of 3-Amino-6,6-dimethyl-2,2-bipyridine. J Chem Soc, Dalton Trans 1993; 3175-3180.

364. Harding MM, Long GV, Brown CL. Solution Conformation of the Antitumour Drug Streptonigrin. J Med Chem 1993; 36:3056-3060.

PAPERS ACCEPTED FOR PUBLICATION (awaiting publication)

1. Omid Hamid, Caroline Robert, Adil Daud, Matteo S. Carlinoe, Tara Mitchell, Peter Hersey, Jacob Schachter, Georgina V. Long, F.Stephen Hodi; Jedd Wolchok, Ana Arance, Jean-Jacques Grob, Anthony Joshua, Jeffrey Weber, Laurent Mortier; Erin Jensen, Scott J. Diede, Blanca Home Moren, Antoni Ribas, Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006, Eur J Cancer, Aug 14 2021, accepted for publication


34

2. Xue Bai, Jiani Hu, Allison Betof Warner, Henry Quach, Christopher Cann, Michael Zhang, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Lalit Pallan, Catriona Harvey, Michael Manos, Olivia Ouyang, Michelle Kim, Gyulnara Kasumova, Justine Cohen, Donald Lawrence, Christine Freedman, Riley Fadden, Krista Rubin, Tatyana Sharova, Dennie Frederick, Keith Flaherty, Osama Rahma, Georgina Long, Alexander Menzies, Jun Guo, Alexander Shoushtari, Douglas Johnson, Ryan Sullivan, and Genevieve Boland, Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in advanced melanoma patients under anti-PD-1 monotherapy, Cancer Research, August 10 2021, accepted for publication

3. Dey, A, Rogiers A, Long GV, Schrieber L, Immunotherapy for Cancer and immune related-adverse events (irAEs), Medicine Today, August 6 2021, accepted for publication

4. A. Zaremba, A.M.M. Eggermont, C. Robert, R. Dummer, S. Ugure, L. Livingstone, P. Ascierto, G. Long, D. Schadendorf, L. Zimmer, The concepts of rechallenge and retreatment in melanoma treated with immune checkpoint blockade, European Journal of Cancer, July 9 2021, accepted for publication.

5. Andrew T. Li, Kavita Vakharia, Serigne Lo, Alexander H.R. Varey, Matteo S. Carlino, Robyn P.M. Saw, Kerwin F. Shannon, Julie R. Howle, Muzib Abdul-Razak, Thomas E. Pennington, Jonathan R. Stretch, Omgo E. Nieweg, Andrew J. Spillane, Georgina V. Long, Alexander M. Menzies, Richard A. Scolyer, John F. Thompson, Sydney Ch’ng, Survival outcomes of salvage metastasectomy after failure of effective systemic therapy for melanoma, Annals of Surgical Oncology, June 25 2021, accepted for publication

6. Tuba N. Gide*, Ines P. Silva*, Camelia Quek, Peter M. Ferguson, Marcel Batten, Ping Shang, Tasnia Ahmed, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, Richard A. Scolyer, Georgina V. Long, James S. Wilmott, Clinical and Molecular Heterogeneity Reveals Distinct Therapeutic Targets in Non-responders to Anti-PD-1+/-Anti-CTLA-4 Immunotherapy in Metastatic Melanoma, Cancers, June 23 2021, accepted for publication

7. K. K Cho, A. E. Cust, Y.M. Foo, G.V. Long, A.M. Menzies, G.D. Eslick, Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis, Melanoma Research, 7 June 2021, accepted for publication

8. Gallagher, S. J., Bailey, T., Rawson, R. V., Mahar, A. M., Thompson, J. F., Long, G. V., Wilmott, J. S., Scolyer, R. A., Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis Pathology. 2021 Jun 2; S0031-3025(21)00108-2. doi: 0.1016/j.pathol.2021.02.012. Online ahead of print. PMID 34090666

9. Cora Waldstein, Wei Wanga, Serigne Lo, Brindha Shivalingam, Gerald B. Fogarty, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Angela M. Hong, Melanoma brain metastasis: The outcome of whole brain radiation therapy in the era of effective systemic therapy, Therapeutic Radiology and Oncology, May 28 2021 accepted for publication

10. Alison J. Potter, Florentia Dimitriou, Rooshdiya Z. Karim, Annabelle Mahar, Charles Chan, Georgina V. Long, Richard A. Scolyer, Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma, Pathology, May 26 2021, accepted for publication

11. Matteo S. Carlino, James Larkin, Georgina V. Long, Checkpoint Inhibitors in Melanoma, The Lancet, May 19 2021, accepted for publication

12. Lisa Haas , Camille Gerard , Anais Elewaut , Izabela Krecioch , Mario Kuttke , Christian Umkehrer , David Hoffmann , Michel Cuendet , Thomas Wiesner , Sakari Vanharanta , Olivier Michielin , Malin Malin Pedersen , Kevin Harrington , Lukas Leiendecker , Maria Novatchkova , Tobias Neumann , Johannes Zuber , Ines Pires de Silva , Sebastian Carotta , James Wilmott , Richard Scolyer , Georgina Long, Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma, Nature Cancer, May 18 2021, accepted for publication

13. F. Stephen Hodi, Jedd D. Wolchok, Dirk Schadendorf, James Larkin, Georgina V. Long, Xiaozhong Qian, Abdel Saci, Tina C. Young, Sujaya Srinivasan, Han Chang, Hao Tang, Megan Wind-Rotolo, Jasmine I. Rizzo, Donald G. Jackson, and Paolo A. Ascierto, Clinical Outcomes by Tumor Mutational Burden and Inflammatory Gene Expression With Combined Nivolumab and Ipilimumab or Monotherapy in Advanced Melanoma, Cancer Immunology Research, April 8 2021, accepted for publication


35

14. Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew M. Haydon, Andrey Meshcheryakov, Muhammad Khattak, Matteo S. Carlino Shahneen Sandhu, Susana Puig, Paolo A. Ascierto, James Larkin, Paul Lorigan, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J M van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. Van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Adjuvant pembrolizumab versus placebo in resected stage III melanoma: Health-Related Quality of Life results from the EORTC 1325-MG/KEYNOTE-054 randomised, double-blind, phase 3 trial, The Lancet Oncology Feb 4 2021, Accepted for Publication

15. G. Marsavela, J. Lee, L. Calapre, S.Q. Wong, M. R. Pereira, A. C. McEvoy, A. L. Reid, C. Robinson, L. Warburton, A. Abed, M. A. Khattak, T. M. Meniawy, S-J. Dawson, S. Sandhu, M.S. Carlino, A. M. Menzies, R. A. Scolyer, G.V. Long, B. Amanuel, M. Millward, M. R. Ziman, H. Rizos, and E. S. Gray Circulating tumour DNA predicts poor outcome from first-, but not second-line treatment with immune checkpoint inhibitors and identifies melanoma patients who will benefit from combination immunotherapy, Clinical Cancer Research, 15 Aug 2020, Accepted for publication

Documents

CV for USYD October 2021 - api.profiles.sydney.edu.au